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“The human enterprise was once largely 
 limited to what Nature produced. We are  
now limited only by what we can imagine.” 1 
 
1. Introduction 
1.1 Definition of Multi Component Reactions 
The always increasing demand for large libraries of compounds readily 
available for High Throughput Screening assays in the discovery process of 
new drugs is allowing more and more the development of new and faster 
methodologies for the rapid construction of novel chemical entities.  
Nowadays, the challenge in synthesis is how a molecule can be made in a 
practical fashion as close as possible to an “ideal” one. In this sense, Multi-
Component Reactions (MCRs) are well known to be selective (minimizing the 
number of by-products), efficient (providing good yields), atom economic, 
time saving, easy to perform requiring readily available (commercial or easy 
to prepare) starting materials.
1
  
 MCRs are ordered pot reactions, where three or more starting materials react 
in a sequence of steps, until a final one, to give a final product which contain 
most of the portions of all the initial components.
2,3 
A MCR is thus a domino 
process by definition.
4,5
  
MCRs allow the formation of several  bonds in one single operation, usually 
without isolating the intermediates, changing reaction conditions and/or 
adding further reagents. The advantages are evident since in multistep 
synthesis temporal and preparative complexity increases in proportion to the 
number of steps. The bond forming efficiency, that is, the number of bonds 
formed in one process, is indeed an important measure introduced by Tietze to 
determine the quality of a MCR.
6
 Creating  several bonds per reactions means 
to generate molecular complexity that means highly efficient processes. 
A major characteristic of MCRs is their high exploratory power: the 
exploration of a very big chemical space with exceptional synthetic efficiency. 
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The structure of the reaction product can easily be diversified by systematic 
variation of each input. The MCRs can be classified according to the reaction 
mechanism, the components involved or their intrinsic variability. As Zhu 
states in Multicomponent Reactions (Zhu, J., Bienaymé, H., Eds.; Wiley: 
Weinheim, 2005),  “The development of novel MCRs is an intellectually 
challenging task since one has to consider not only the reactivity match of the 
starting materials but also the reactivities of the intermediate molecules 
generated in situ, their compatibility and their compartmentalization.” Finally 
it is important to point out that MCRs have already had an important role in 
drug development, from lead discovery to lead optimization to production, 
even before the advent of  combinatorial technologies as demonstrated by the 
identification of nifedipine (Adalat®), a highly active calcium antagonist, by 
means of a Hantzsch reaction or by the synthesis of piperazine-2-carboxamide, 
the core structure of the HIV protease inhibitor Crixivan, by a Ugi-4CR.  
 
 
 
1.2  Some History of MCRs 
The general ordering principle of MCRs is followed by the α-amino alkylation, 
in which an oxo compound and a primary or a secondary amine undergoes 
electrophilic addition to an electron-rich position of a molecule.
 7
 The Strecker 
synthesis of α-amino acids via α-amino cyanides was first published in 1850 
and is generally considered to be the first MCR.
8 
In this reaction an aldehyde 
is condensed with ammonium chloride in the presence of potassium cyanide 
to form an α-aminonitrile, which is subsequently hydrolyzed to give the 
desired amino acid (Table 1). 
Many important heterocycle synthesis are MCRs. 1,4-dihydropyridines were 
first synthesized over one hundred years ago in a four component reaction by 
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Hantzsch (H-4CR) from ammonia, aldehyde  and  two equivalents of 
acetoacetic ester.
9
 After half a century, at the Bayer AG company, a very 
successful dihydropyridine preparation for the therapy of cardiovascular 
disease named Nifedipin was developed, based on the Hantzsch synthesis.
10
  
 
 
[a] T = Thymine 
Table 1. Examples of some historically significant MCRs. Many of them are 
based on the reactivity of carbonyl or imine groups.  
 
Other very famous and useful MCRs are the Biginelli and the Mannich 
reactions discovered in 1891 and 1912. The Biginelli reaction affords 3,4-
dihydropyrimidin-2(1H)-ones starting from ethylacetoacetate, an aldehyde 
and urea. The Mannich reaction consists of an amino alkylation of an acidic 
proton placed next to a carbonyl functional group with formaldehyde and 
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ammonia or any primary or secondary amine; the final product is a β-
aminocarbonyl compound also known as a Mannich base.  
In 1921, the first MCR involving an isocyanide, the Passerini reaction (P-3CR) 
was reported. 
A further important MCR is the Bucherer-Bergs reaction (BB-4CR).
 11
 It can 
be understood as an extension  of the S-3CR using an additional component 
(CO2). Whereas the Strecker 3-CR is an equilibrium reaction and often 
delivers the product in unsatisfactory yields, the BB-4CR is practically 
irreversible upon addition of CO2. It still is an important method for the 
synthesis of unnatural α-amino acids. 
 
1.3  Isocyanides, Preparation and Chemistry 
A large and important class of MCRs are the Isocyanide Multi-Component 
Reactions (IMCRs).  Isocyanides are the only class of stable organic 
compounds with a formally divalent carbon. In exothermic reactions C
II
 is 
oxidized to C
IV
.
12
 Most of volatile isocyanides have a strange repulsive odor 
described from Gautier as “reminiscent of artichokes and phosphorus at the 
same time”.13 People who inhaled volatile isocyanides such as allyl, benzyl, 
methyl, or tert-butyl isocyanide over a long period of time reported  the 
sensory perception of the smell of hay
3
 and a prolonged inhalation is said to 
increase the intensity of dreams at night. Higher molecular weight isocyanides 
are often solid and odorless. This class of compounds showed however to 
have only a slight toxicity, apart from few exceptions.
 
Isocyanides were first 
synthesized in 1859 by Lieke, who did not recognize them and believed them 
to be nitriles.
14 
It was Gautier the first to understand the isomeric relationship 
between isocyanides and nitriles in 1869.
15 
At the same time Hofmann
16
 found 
a new approach to isocyanides with the reaction of primary amines
 
with 
potash and chloroform (Scheme 1). Anyway, all methods known at that time 
were complicated, poorly generalizable and low yields affected, with difficult 
separation of isocyanides from their isomeric accompanying nitriles.  
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Scheme 1. The Hofmann carbylamine reaction. 
 
Nowadays there are many convenient and effective methods to access to 
isocyanides  that can be divided into seven different basic routes:   
1) Alkylation and alkynylation of cyanides; 2) Reaction of primary amines 
with dichlorocarbene; 3) Dehydration of N-formamides; 4) Further 
elaboration of isocyanides; 5) Use of organometallic isocyanides; 6) 
Reduction of isocyanates, isothiocyanates, isoselenocyanates, and isocyanide 
dihalides; 7) Miscellaneous methods.
 17
 
The method of choice regarding cost, yield and execution remains however 
the dehydration of the corresponding N-formamides with inorganic 
dehydratants and organic matching bases, such as POCl3 or Phosgene, and 
Triethylamine.
18
  
 
Isocyanide chemistry is characterized by three properties: the α-acidity, the α-
addition, an intrinsic high affinity toward metallorganic reagents and their 
subsequent reactions, and the easy formation of radicals. Especially phenyl-
isocyanides are substrates for radical-induced cyclizations. The α-acidity is 
increased by the presence of electron-withdrawing substituents in the α-
position. α-metalated isocyanides can be seen as easy-to-handle α-amino 
anion equivalents, very useful for the synthesis of α, β-unsaturated 
isocyanides, heterocycles and amino acids.
19
 Isocyanides polymerize under 
Lewis acid catalysis to polyiminomethylenes.
20
 Synthetically, the most 
important property of isocyanides is the reaction with nucleophiles and 
electrophiles at the isocyanide carbon atom: the “α-addition”, leading to the 
“α-adduct”. Most other functional groups in organic chemistry react with 
nucleophiles and electrophiles at different centers. Only carbene and carbon 
monoxide share this property with the isocyanides. The different reactivities 
of the isomeric nitriles and isocyanides  are to be ascribed to the higher orbital 
coefficient of the isocyanides at the carbon atom in the π* orbital, compared 
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to nitriles, which leads to nucleophlic attack of the carbon atom. Electrophiles 
react with the σ orbital of the HOMO-1 and therefore also with the carbon 
atom.  Nitriles instead are attacked by nucleophiles at the carbon atom (higher 
π* orbital coefficient) and by electrophiles at the nitrogen atom (higher π 
orbital coefficient).  The great potential of isocyanides for the development of 
MCRs lies in the diversity of bond forming processes available, their 
functional group tolerance, and the high level of chemo- and regio-selectivity 
often observed.  
 
 
Figure1. Qualitative comparison of the frontier orbitals of isocyanides and 
nitriles, showing the different reactivities of the two isomeric functional 
groups. 
 
1.4  Passerini 3-CR and Ugi 4-CR  
Today most MCRs chemistry performed with isocyanides relates to the 
classical reactions of Passerini and Ugi, and most part of nowadays described 
IMCRs was born as their modifications or combinations with other types of 
reactions. Passerini reaction, described for the first time in 1921, involves an 
oxo-component (an aldehyde or a ketone), an isocyanide and a nucleophile 
(typically a carboxylic acid) to afford α-acyloxycarboxamides.  Ugi reaction 
could be seen as the aza-version of the Passerini 3-CR, as it involves an amine 
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as additional fourth component: it is indeed the reaction of a Schiff base or an 
enamine with a nucleophile and an isocyanide affording α-acylaminoamides. 
The Ugi 4-CR is much more versatile than the Passerini in terms of library 
size and scaffold.  The mechanisms of these reactions have often been 
discussed
21
 ; kinetic and preparative investigations have led to different 
mechanistic suggestions.
22
  In contrast to the Ugi 4-CR, the Passerini 3-CR is 
accelerated by aprotic solvents, indicating a nonionic mechanism. Passerini 
himself postulated hemiacetals between the carboxylic acid  and the oxo 
component as intermediates. From kinetic studies and the observation of a 
third-degree reaction order, bipolar intermediates were assumed. Other 
Authors have discussed N-protonated isocyanides as reactive intermediates. A 
plausible mechanism which agrees with experimental data is the formation of 
a loosely hydrogen-bonded adduct 4 from a carbonyl compound 1 and a 
carboxylic acid 2, followed by the α-addition of the electrophilic carbonyl 
carbon and the nucleophilic oxygen atom of the carboxylic acid to the 
isocyanide carbon of 3 (Scheme 2) under formation of a cyclic transition state 
with all three parent compounds. The α-adduct 5, which cannot be isolated23, 
rearranges in an intramolecular transacylation to the stable α-
acyloxycarboxyamide 6. 
 
 
Scheme 2. Suggested mechanism of P-3CR. 
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The Passerini reaction is carried out at high concentrations of the starting 
materials and in inert solvents at or below room temperature. The P-3CR is 
particularly suitable for the synthesis of compounds containing the α-acyloxy 
carboxamide group. The easily performed reduction of Passerini products 
opens the way to a multitude of  N-substituted β-hydroxyamines. The 
mechanistic scenario for the U-4CR may be different and more complex than 
that shown for the P-3CR. First of all the U-4CR is favored in a polar solvent 
(MeOH being the most common) in contrast the P-3CR. A strongly simplified 
reaction mechanism is showed in Scheme 3. In the first step the oxo 
component and the amine condense to the imine, the Schiff base, via a 
hydroxyl aminal. It is also possible that the hydroxyl aminal can be 
transformed directly in the course of the reaction without formation of a 
Schiff base under certain circumstances. Imines can be seen as carbonyl 
analogues. Like most imine reactions, the U-4CR runs better upon activation 
of the Schiff base. For this, the acid component protonates the nitrogen atom 
of the Schiff  base, thus increasing the electrophilicity of the C=N bond. 
Another way to increase the electrophilicity of the imines is the addition of a 
Lewis acid such as TiCl4 or BF3· OEt2, being especially the case for electron-
rich, weakly electrophilic Schiff bases.  Depending on the solvent, the ions 
can be present as a salt pair or separately. The electrophilic iminium ion and 
the nucleophilic acid anion add to the isocyanide carbon atom. The α-adduct 
thus formed can be seen as a hetero analogue of an acid anhydride in which an 
exo-oxygen atom has been substituted by an NR group. Acid anhydrides are 
strong acylating agents,  as are their heteroanalogues formed here. The 
acylable atom is the nitrogen of the former amine. After an intramolecular 
acylation, the stable Ugi linear, peptide-like adduct is obtained. This type of 
intramolecular acylation was first described in 1910 by Mumm and was 
subsequently called the Mumm rearrangement.
24
All elementary steps of this 
reaction are equilibria; however, the last step, the rearrangement to the stable 
α-acylaminoamide, lied exclusively on the product side. The driving force of 
the total reaction sequence is the oxidation of the isocyanide C
II
 atom to the 
amide C
IV
 atom. It is interesting to follow the changes in nucleophilia and 
electrophilia of the components during the U-4CR. In the course of the 
individual steps the reactive centers of the acid component and the imines 
change the sign of their reactivity several times. At first the C=N bond of the 
imine behaves like a base towards the acid component. Then the protonated 
Schiff base functions as the electrophilic and the acid anion as the 
nucleophilic component of the α-addition. Due to the α-addition to the 
isocyanide, the amine nitrogen atom becomes the nucleophilic reaction 
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partner of the electrophilic O-acylcarboxylic acid amide system in the α-
adduct. In the course of the cycloaddition and the elimination, the reactive 
centres change their philia signs once again. In the course of the U-4CR, one 
C-C bond and several heteroatom-C bonds are newly formed. The diversity of 
the basic structures of the U-4CR is primarily due to the variety of the acid 
components and their rearrangement opportunities, but also to the structures 
of the amines as well as the many intramolecular variations. McFarland was 
the first to examine the product distribution of the U-4CR depending on 
different reaction conditions systematically. Isocyanides reactivity is mainly 
influenced by inductive and mesomeric and to a lesser extent by steric effects. 
The reactants concentration is much more important than the properties of the 
solvent. Generally the reaction proceeds better if the reactants are present in 
high concentrations, that is 0.5 to 2 molar. Low-molecular-weight alcohols, 
such as methanol, ethanol or trifluoroethanol are used as solvents. Aprotic 
polar solvents like DMF, dichloromethane and THF, or also aprotic apolar 
solvents such as chloroform or dioxane have also been described as 
advantageous. In addition, the U-4CR can be performed in biphasic, aqueous 
solvent mixtures.  
 
 
Scheme 3. Simplified reaction mechanism of U-4CR. 
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2. Post-condensation modifications 
 
2.1 Introduction to post-condensation modifications 
Multicomponent reactions are an extremely powerful synthetic tool for 
medicinal chemistry and pharmaceutical industry not only for all the already 
mentioned advantages, but also because after a scaffold is synthesized, it can 
be used for other post-modifications depending on the functional groups 
introduced during the MCR. In this way it is really simple and fast to 
synthesize large libraries of structurally diverse complex molecules for 
biological screenings. Potentially, the number of post-condensation 
modificationsare countless relying on the chemistry offer: classic textbooks 
organic reactions such as Pictet- Spengler cyclization,
1
 intramolecular Diels-
Alder,
2
 Mitsunobu reaction and acyl migration,
3
 Knovenagel condensation,
4
 
amide reduction,
5
 metathesis reaction,
6
 just to cite few of them, or also 
sequential multi-component transformations as Ugi-Ugi
7
 and Ugi-Petasis.
8
 In 
this chapter,  two projects related with post-modifications reaction after a 
classical MCR will be presented. The first one deals with an attempt to 
synthesize benzo-oxazepinediones, while the second deals with the synthesis 
of 1-Aryl-5-Aroyl Tetrazoles.
9
 The following projects have been investigated 
under the supervision of Prof. Gian Cesare Tron.  
 
2.2 Buchwald-Hartwig/Goldberg trans-amidation as modification 
of a 3-C Passerini reaction adduct.  
This project aimed at the synthesis of benzo-oxazepinediones of general 
structure 1 through a sequence of a classical Passerini 3-CR and an 
intramolecular N-arylation reaction under Buchwald-Hartwig or Goldberg 
conditions. There are many examples in literature of Passerini 3-CR followed 
by post-condensation transformations as intramolecular Wittig-type 
reactions
10
, N-deprotection/ O- to N-acyl migration
11
, ring-closing 
metathesis
12
 (RCM), and others.  
   
13 
 
 
Figure 1. Target benzo-oxazepine dione structure 
 
The Passerini product to use as test-substrate  for cyclization reactions was 
obtained by reacting  heptanal, n- pentylisocyanide and 2-iodobenzoic acid, in 
dichlorometane as solvent, to afford 1-(ethylamino)-1-oxobutan-2-yl-2-
iodobenzoato 2, in  59% yield. (For details on the mechanism see the 
Introduction). This adduct was then used as test substrate to screen a wide 
range of reaction conditions for the transition metal- catalyzed cross coupling  
amide N-arylation reaction.  
 
Scheme 1. Passerini 3-CR for the synthesis of the test substrate for N-
arylation cyclizations reaction.  
 
2.3 Buchwald-Hartwig N-arylation reaction: important features. 
The Buchwald-Hartwig N-arylation reaction is an aryl halogen/ amide 
exchange in order to form a new C-N bond performed in the presence of a 
palladium source as catalyst, a phosphine as ligand and a non-nucleophilic 
organic or inorganic strong base. This type of reaction is mainly used for 
amination of aryl halides, formation of aryl ethers through reaction with 
alcohols, and formation of new C-C bonds in α-arylation of carbonyl, 
arylation of ketones, aldehydes, esters, γ-arylation of enones and others.  The 
first example of a trans-amination reaction of an aryl halide palladium 
catalyzed was published in 1983 by Migita
13
; this reaction employed aryl 
bromides and aminotin compounds providing the corresponding aniline 
14 
 
derivatives in moderate to good yields, in the presence of tri-o-tolylphosphine 
palladium (0). The limitations associated with the use of toxic and quite 
unstable tin derivatives were overcome by Buchwald
14
 and Hartwig
15
 in 1995, 
who independently described a tin-free procedure. They generated the amide 
in situ, starting from an amine and a strong base, that was for Buchwald 
sodium tert-butoxide and for Hartwig the lithium hexamethyldisilazide 
(LiHMDS). Among all the efforts to increase the scope of substrates and the 
efficiency of the reaction, fine tuning of the ligands has shown the biggest 
impact. Subsequent research allowed to identify a large number of ligands, 
many of which are now commercially available. 
 
 
Scheme 2. Migita trans amination reaction. 
 
 
Scheme 3. Modifications by Buchwald and Hartwig of Migita trans-
amination reaction conditions. 
 
They are bisphosphonane chelating ligands such as binap
16
 (2,2'-
bis(diphenylphosphino)-1,1'-binaphthyl) a (figure 2) and dppf
17
 (1,1'-
Bis(diphenylphosphino)ferrocene) b in an early stage and then derivatives 
such as XantPhos c, or monodentate phosphanes such as dialkyl- 
biarylphosphanes d-g. Best results were obtained with dialkylbiaryl 
phosphane ligands: they often allows, indeed, short reaction times, low 
catalyst loadings, and mild reactions conditions.  
15 
 
 
 
Figure 2. Examples of chelating phosphanes (a-c), and biaryl phosphanes (d-
g).  
To further optimize catalyst design, much attention has been directed towards 
a deep understanding of these effects and an intensive study of the mechanism 
of the palladium catalyzed amination with numerous ligand systems.   
The Pd
II
 catalyst is reduced to the active Pd
0
 species  which is stabilized by 
the ligand L (1). In the case of the dialkylbiaryl phosphanes the catalytically 
active species is believed to be the mono-ligated, highly reactive [LPd
0
] 
complex, which exists in equilibrium with the [L2Pd
0
] species.
18
 The catalytic 
cycle starts with coordination of the aryl halide to palladium (0) followed by 
oxidative addition to intermediate 2. In the next step  a halide atom is replaced 
by the nitrogen atom of the amine to intermediate 3. The enhanced acidicity of 
the amine when coordinated to palladium allows these compound to be 
deprotonated with a strong base to give intermediate 4. This latter give the 
reductive elimination to the desired aryl amine 5 liberating [LPd
0
] species 
ready to start a new cycle.  
 
16 
 
 
 
Figure 2. Proposed catalytic cycle. 
substituents on the lower ring play a role in promoting the formation of the reactive [LPd
0
] 
species.  Other studies demonstrated, through deuterium labeling, that in case of 2’-
monosubstituted dialkylbiaryl ligands, the Pd
II
 precatalysts have a tendency to form 
palladacycles 
20 
3 (Figure 3). This effect would serve to reduce the rate of catalyst 
activation, as such palladacycle are only slowly converted into the active catalyst.
21
 
Another characteristic of the dialkyl phosphane ligands which is believed to promote 
catalyst stability and increase electron density at the metal center is the possibility of 
palladium-arene interactions between the metal atom and the lower ring of the ligands (4, 
Figure 3). 
 
 
Figure 3. Example of palladacycle 3, and interaction palladium-arene in 4.  
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Such interactions have been observed in the X-ray crystal structures of a 
number of palladium-biaryl phosphane complexes,
22-28
 and even in an 
oxidative addition complex with methyl triflate.
29
 Anyway, obtaining 
experimental informations on the importance of these interactions in the 
catalytically active species has proven to be more difficult.
30
 DFT calculations, 
however, have underlined the importance of the palladium-arene interactions 
in intermediates in the catalytic cycle.
31,32
 Finally, these studies also indicated 
that the lower ring promotes the reductive elimination step. The palladium-
arene interaction stabilizes the aminopalladium intermediate and reduces the 
energy of the transition state when the palladium center is proximal to the 
lower ring (Figure 4). In a recent review
33
, Hartwig enlightened the electronic 
effects on reductive elimination from palladium (II) complexes.   He stated 
that in many cases the scope of the cross coupling is controlled by the rate and 
scope of the reductive elimination process. For example, palladium-catalyzed 
couplings to form C-N and C-O bonds were challenging to develop because 
palladium amido and palladium alkoxo complexes were reluctant to undergo 
reductive elimination.
34 
Until recently, it was unclear whether all classes of C-
X bond-forming reductive elimination processes would depend equally on the 
overall electron density at the metal center or whether each process would be 
controlled by its own set of electronic effects. Dealing with steric effects, it is 
generally true that complexes with more hindered ancillary ligands undergo 
reductive elimination faster than complexes with less hindered ancillary 
ligands. This effect presumably arises from a relief in steric congestion upon 
generation of the free organic product and a resulting metal center with a 
reduced coordination number.  For electronic effects, mainly two were 
observed. First reductive elimination is usually slower from more electron-
rich complexes than from electron-poor ones. This effect can be explained by 
the observation that strongly donating ancillary ligands make the metal center 
more electron-rich, and electron-rich metal centers tend to undergo reductive 
processes more slowly than electron-poor metal centers. Second, theoretical 
and early experimental studies suggested that complexes with more strongly 
electron-donating reacting ligands undergo concerted reductive eliminations 
faster than do complexes with more weakly electron-donating reacting ligands. 
An explanation for this effect could be the consideration that electron-
withdrawing groups on the reactive ligand  lead to an increase in the strength 
of the M-C or M-X bond. These electron-withdrawing groups make the M-C 
or M-X bond more ionic, and this ionic character increases the 
thermodynamic bond strength. Thus, groups whose electronic properties 
18 
 
increase the strength of the M-C bonds tend to decrease the thermodynamic 
driving force for reductive elimination.  
Experimental data on electronic effects on C-N bond-forming reductive 
elimination show that this process in arylamines is faster from complexes with 
more electron-rich amido ligands than from complexes with more electron-
poor amido ligands.
35
 
 
 
 
Figure 4. Important structural features of dialkylbiaryl phosphanes. 
 
2.4 Goldberg reaction: an overview. 
In the Goldberg reaction an amine or an amide is coupled with an aryl halide 
in the presence of a stoichiometric amount of copper as catalyst, and a base. 
(Scheme 4) It is a variation of the Ullmann condensation between a phenol 
and an aryl halide to afford a diaryl ether (Scheme 5).
36
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Scheme 4. Goldberg condensation. 
 
 
Scheme 5. Ullmann condensation. 
 
Both the Ullmann and the Goldberg reactions predate the palladium-catalyzed 
amination methodology by many decades. Nevertheless, the methods have 
remained relatively  undeveloped. The necessity to use temperatures as high 
as 210°C, highly polar solvents, and often large amounts of copper reagents, 
as well as the modest yields often realized, have undoubtedly prevented these 
reactions from being employed to their full potential. An important alternative 
has been reported where aryl boronic acids are used as arylating agents 
instead of aryl halides.
37 
Unluckily, the method suffers from high costs and 
poor availability of functionalized boronic acids, as well as limited scope of 
the process. The traditional protocol for Goldberg amidation reaction 
prescribe simple copper salts or often copper metal as catalyst. Very few 
reports have focused on deliberate use of ligands to facilitate the copper 
catalyzed amidation reaction, until, in 2002, Buchwald reported an 
experimentally simple and inexpensive catalyst system for the amidation of 
aryl halides by using 0.2-10% mol of CuI, 5-20% mol of a 1,2-diamine ligand, 
and K3PO4, K2CO3 or Cs2CO3 as base (Scheme 6).
38
 This  system proved to be 
extremely efficient and general for N-amidation of aryl and heteroaryl iodides 
and bromides, and in some cases even unactivated aryl chlorides. The reaction 
scope was extended using N,N’-dimethylethylenediamine and trans-N,N’-
dimethyl-1,2-cyclohexanediamine as ligand.  
20 
 
 
 
 
Scheme 6. Buchwald modification of Goldberg amidation reaction conditions.  
 
In this study Buchwald reported a variety of effective 1,2-diamine ligands; 
their structure has a pronounced effect on their ability to facilitate the copper-
catalyzed aryl amidation reactions. The degree of substitution and 
consequently the steric bulk of diamine ligands play the most important role. 
The N,N’-dimethyldiamine L2 and L5 have higher activity than the 
unsubstituted diamines L1, L3 and L4. On the other end, bulky N-substituents 
on the ligand, e.g. isopropyl as in L7 and ethyl as in L6 decrease the rate of 
aryl amidation reaction. Further substitution at the nitrogen center leads to a 
completely inactive ligand (e.g. TMEDA). Ligands L2 and L5 are 
commercially available, and ligand L5 showed to be slightly more active than 
L2; the difference becomes significant in more difficult reactions such as in 
the amidation of aryl chlorides. The role of the chelating amine could simply 
be to increase the stability constant of the catalycally active copper-amine 
complex. Anyway, further studies are required to ascertain this hypothesis. 
Different readily available copper sources were also tested, and Cu2O, CuI 
and CuCl produced acceptable results, being the air-stable and inexpensive 
CuI the best one with more difficult substrates. It is interesting to note that 
copper compounds in various oxidation states are catalytically active and 
presumably are transformed to the same active catalyst under the reaction 
conditions.
39
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Figure 5. Some diamine ligands in Buchwald version of Goldberg amidation. 
 
The choice of the base plays a more important role than the nature of the 
copper precatalyst. Amidation of aryl iodides proceeds best with K3PO4 as 
base; the reaction is much slower with K2CO3. In contrast many amidations of 
aryl bromides, which typically react more slowly than aryl iodides, fail in the 
presence of K3PO4. In those cases, complete conversion of the aryl bromide 
can nevertheless be achieved with a weaker base such as K2CO3. Further 
insight into this interesting phenomenon was provided by an experiment 
where a solution of a strong base, KHMDS, was slowly added to a reaction 
mixture including an aryl iodide and an amide: nearly complete conversion 
was achieved while less of 1% conversion was detected if the base was added 
in a single portion. These observations suggest that the rate of deprotonation 
of the amide has to match the rate of amidation reaction. If an excess of 
deprotonated amide is formed, it impedes the desired aryl amidation reaction 
presumably via formation of an unreactive cuprate complex (Scheme 7). 
Experimental data with organic bases demonstrated that the pKHA of the base 
employed in the arylation reaction should be below the pKHA of the amide 
substrate unless the base is delivered gradually as the reaction proceeds. A 
similar rational can be applied to inorganic bases such as K3PO4 or K2CO3. 
Presumably these bases are thermodynamically very strong in aprotic 
solvents
40
; nevertheless, their extremely low solubility in nonpolar organic 
solvents ensures the rates of deprotonation that are optimal for the arylation of 
amides.  
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Scheme 7. Catalytic cycle of Goldberg amidation, and formation of 
unreactive cuprate complexes.  
 
This catalytic system provides an excellent complement to the palladium-
catalyzed methodology, particularly if aryl halides with strong electron-
donating groups or free N-H groups have to be amidated. There are also some 
practical benefits of this copper-diamine-catalyzed amidation protocol. 
Although the reactions are moderately sensitive to oxygen and have to be 
performed under inert atmosphere, there is no need to use glove-box 
techniques nor to purify the commercially available reagents. Most of the 
reactions are extremely clean: no reduction or homocoupling of the aryl halide, 
which often  takes place in the Pd-catalyzed cross-coupling reactions, is 
normally observed. Another notable feature of the process is the low 
molecular weight of diamine ligands: this is a definitive advantage if the cost 
per mole of the ligand is considered. A more recent paper by Buchwald
42
 
describes initial insight into the mechanism of aryl iodide activation, 
complementing the kinetic study of a Cu(I)-catalyzed Goldberg reaction with 
a direct N- arylation of a Cu(I) amidate. Anyway the precise mechanism of the 
Cu(I)-mediated activation has not been established precisely and warrants 
further studies.  
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2.5 Buchwald-Hartwig/ Goldberg experimented conditions on 
Passerini adduct 2. 
In the attempt to obtain our benzoxazepinic scaffold starting from the P-3CR 
adduct 2 we unsuccessfully experimented different copper catalyzed Goldberg 
amidation reactions, (Scheme 8) selecting from literature examples of linear 
secondary and cyclic amidic substrate.
42-47
 We chose cooper iodide (CuI) as 
catalyst, and the 1,2-diamine ligands L2 and L5. We also used thiophene-2-
carboxylic acid L8 as ligand (Figure 6) which has been reported by Zhu to 
successfully afford benzodiazepindiones derivatives in a Buchwald-Hartwig 
copper catalyzed amidation reaction.
43
  
 
 
Figure 6. Thiophene-2-carboxylic acid. 
 
Another tested procedure was by Lange
44
 using N-methyl-2-pyrrolidinone 
(NMP) as solvent. The reaction is described to be very fast under Microwave 
irradiation, but it is possible to have a quite complete conversion of the 
substrate experimented even at room temperature. As reported in Table 1, 
solvents tested were toluene (the classical solvent described for this reaction) 
(entry 2,3,6,7,10) , but also DMSO (entry 1), dioxane (entry 9), NMP (entry 
5), THF (entry 4) and mix toluene/CH3CN (entry 8). The screened bases in 
our reaction conditions were K2CO3 (entry 1-3,5,6,8) and Cs2CO3 (4,7,9,10).  
 
Scheme 8. Attempted cyclizations of Passerini adduct 2. 
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Unfortunately, all the experimented conditions failed to afford the desired 
product. We were only able to recover the unreacted α-acyloxy-amide 2. 
When higher temperatures were used (as in entry 5) we only observed 
degradation of the starting substrate to an intractable mixture. When required, 
air-free conditions were used, with degassed solvents, and the reactions 
performed in a Schlenk tube under a positive pressure of nitrogen.  
 
Entry Catalyst Ligand Base 
Solv./ 
Temp 
Tim
e 
1 
CuI 
10% mol 
L8      
20%mol 
K2CO3 2 
eq 
DMSO 
110°C 
20h 
2 
CuI  
5% mol 
L2 
10%mol 
K2CO3    
2 eq 
Toluene 
100°C 
20h 
3 
   CuI  
5% mol 
 L5     
10%mol 
        
K2CO3      
2 eq 
 Toluene 
110°C 
20h      
4 
CuI  
20% mol 
L2      
40%mol 
Cs2CO3    
2 eq 
THF 
60°C 
20h 
5 
CuI  
2.5% mol 
------- 
K2CO3      
1 eq 
NMP 
180°C 
17h 
6 
CuI  
5% mol 
L2      
10%mol 
K2CO3    
2 eq 
Toluene 
180°C 
20h 
7 
Pd(OAc)2 
3.3% mol 
L9    
5%mol 
Cs2CO3 
1.4 eq 
Toluene 
100°C 
24h 
8 
Pd(OAc)2 
5% mol 
L9    
5%mol 
K2CO3      
2 eq 
Tol/CH3
CN 
100°C 
24h 
9 
Pd(dba)3 
2% mol 
L10    
6% mol 
Cs2CO3 
1.4 eq 
Dioxane 
110°C 
24h 
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10 
Pd(OAc)2 
3.3% mol 
L10  
5%mol 
Cs2CO3 
1.4 eq 
Toluene 
100°C 
24h 
 
Table 1. Buchwald-Goldberg experimented conditions. 
 
Table 1 also reports Buchwald-Hartwig palladium catalyzed amidation 
experimental reaction conditions. Use of  palladium acetate (entry 7,8,10) and 
tris(dibenzylideneacetone) dipalladium  (entry 9) is reported. Two different 
phosphines (L9, L10) were used as ligands (Figure 7).  
 
 
Figure 7. Phosphine ligands used in test reactions. 
 
2.6 Synthesis of 1-Aryl-5-Aroyl Tetrazole derivatives using an 
Ugi-like 4-component reaction followed by a biomimetic 
transamination. 
This project aimed to identify a novel and operationally simple strategy for 
the synthesis of elusive 1-aryl-5-aroyl tetrazoles by means of an Ugi-like four 
component reaction (4-CR), followed by a hydrogenolysis/transamination 
post-transformation. The superimposition between a potent anti-tubulinic 
chalcone and 1-aryl-5-aroyl tetrazoles revealed that, potentially, this scaffold 
could be a bioisostere
48
 of chalcones and so could generate metabolically 
stable
49
 chalcone-like analogues with anti-tubulinic activity (Figure 7).  
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Figure 7. Superimposition between a potent anti-tubulinic chalcone and 1-
aryl-5-aroyl tetrazoles. 
Surprisingly, a Sci-Finder® and CrossFire® survey revealed that only four 1-
aryl-5-aroyl tetrazoles (Figure 8) have been reported to date and only two 
synthetic strategies have been reported with poor chemo-selective and low 
yield synthetic routes developed (Figure 9). 
 
 
Figure 8. 1-aryl-5-aroyl tetrazoles reported in literature. 
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Figure 9. Reported syntheses for the generation of 1-aryl-5-aroyl tetrazoles. 
 
In the first strategy, nitrones react with hydrazoic acid followed by an 
intramolecular [1,3]-cycloaddition
50
, while the second synthetic strategy 
consists in the reaction between isocyanides and acyl chlorides to give α- 
ketoimidoyl chlorides which undergo nucleophilic substitution with an excess 
of hydrazoic acid, followed by an intramolecular [1,3]-cycloaddition.
51
 Very 
recently, Sharpless’ group has devised a synthesis of 5-acyltetrazoles from 
azides and acyl cyanides, but the reaction was incompatible with aryl azides 
in order to generate 1-aryl-5-aroyl tetrazoles.
52
 
In a first attempt, we envisaged the possibility to synthesize this scaffold 
through a Passerini 3-CR using trimethylsilyl azide in the place of the acidic 
component, followed by an oxidation step (Scheme 9). 
 
Scheme 9. First retrosynthetic analysis. 
It is interesting to notice that, in a comprehensive review on Passerini reaction 
by Banfi et al., there are no examples of tetrazole scaffolds generated by 
aromatic aldehydes and aromatic isocyanides.
53
 When we reacted 3,4,5-
trimethoxyphenylisocyanide (1), p-anisaldehyde (2) and trimethylsilyl azide 
(3) in dichloromethane at room temperature, we could only isolate the 3,4,5- 
trimethoxyphenyl-1H-tetrazole (4) in 90 % yield (Scheme 10).
 54
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Scheme 10. Formation of 3,4,5-trimethoxyphenyl-1H-tetrazole (4). 
We therefore screened different Lewis acids as catalysts (zinc triflate, lithium 
bromide, indium trichloride, zinc chloride, aluminium trichloride, cerium 
trichloride, ytterbium triflate, boron trifluoride and dysprosium acetate) in 
order to activate the aldehyde component. Our test reactions revealed that 
AlCl3 was the only catalyst able to promote the multicomponent process, 
affording, after column chromatography, in 30 % yield an inseparable mixture 
formed by the desired tetrazole compound (9) and the α-hydroxy-amide 
product (10) in a 1:1 ratio. This latter derives from water addition to the 
intermediate nitrilium ion (Scheme 11). Attempts to avoid the formation of 10, 
using anhydrous sodium sulphate, 4 Å molecular sieves or ultra dry AlCl3 did 
not suppress the formation of the by-product 10. 
 
Scheme 11. MCR between an aromatic isocyanide, an aromatic aldehyde and 
trimethylsilyl azide catalyzed by aluminum trichloride. 
Recently Zhu and co-workers demonstrated that the formation of the α-
hydroxyamide derivatives depends on the catalyst and cannot be suppressed.
55
 
In this paper Zhu described the asymmetric synthesis of 5-(1-
29 
 
Hydroxyalkyl)tetrazoles by a catalytic enantioselective Passerini-type reaction. 
Isobutyraldehyde 11, 4-methoxyphenylisocyanide 12 and TMSN3 7 were used 
as test reaction components, at 0°C and in the presence of catalyst 13. The test 
reaction afforded the desired tetrazole and a significant amount of 2-hydroxy-
N-(4-methoxy-phenyl)-3-methylbutanamide 16.  
 
Scheme 12. Passerini 3-CR test reaction reported by Zhu.  
 
 
Figure 10. Catalyst used in the asymmetric P-3CR by Zhu.  
 
Decreasing the reaction temperature, using additives (Na2SO4, 4 Å molecular 
sieves) or using HN3 did not avoid the formation of 16. Control experiments 
indicated that in the absence of Al catalyst under otherwise identical reaction 
conditions, formation of 16 did not occur and the yield of 15 was significantly 
reduced. These results indicated that the formation of both 15 and 16 was 
catalyzed by [(salen)Al
III
Cl] complex 13. Reasoning that reaction of TMSN3 
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or HN3 with 13 might produce TMSCl (or HCl), with concurrent generation 
of an Al-azide complex, a potential mechanism for the formation of 15 and 16 
was proposed. Herein, nucleophilic addition of isocyanide  to the aldehyde-Al 
complex (A) affords the nitrilium ion (B), which is trapped by hydrazoic acid 
to provide tetrazole D. Concurrently, reaction of B with TMSCl or HCl 
affords the chloroimidate C, which in the presence of adventitious water, is 
converted into the α-hydroxyamide E. Finally they succeded to synthesize the 
desired tetrazole 15 in almost quantitative yield and 83% ee with 
[(salen)Al
III
Me] catalyst 14.  
 
 
 
Scheme 13. Proposed mechanism of α-hydroxyamide side product E 
formation. 
 
In light of that, our strategy based on P-3CR was therefore abandoned, as it 
suffered from low yields, formation of by-products and difficult purification, 
features incompatible with the generation of a library during the drug 
discovery process. We consequently devised another retrosynthetic analysis, 
always using a MCR as key step for the introduction of all the functionalities 
in one single operation. In practice, the carbonyl group of 1-aryl-5-aroyl 
31 
 
tetrazoles could be created through a transamination/oxidation reaction. The 
amine intermediate would derive from an Ugi-like 4CR using benzylamine, 
arylisocyanide, arylaldehyde and trimethylsilyl azide
56,57
 
 
followed by a 
hydrogenolytic cleavage of the N-benzyl group (Scheme 14). 
 
 
Scheme 14. Second retrosynthetic analysis. 
 
Initial experiments were carried out using benzylamine (17), trimethylsilyl 
azide (7), 4-methoxyphenylisocyanide (18) and 3,4,5-trimethoxybenzaldehyde 
(19) as test substrates. The four compounds reacted in methanol at room 
temperature affording after 20 hours the desired adduct (20) which 
precipitated and could be collected by simple filtration in 59 % yield. 
Compound 20 was then hydrogenolyzed to cleave the benzyl group, using 
palladium on charcoal 10 % as catalyst, in methanol at 60°C providing, after 
filtration over a celite pad and evaporation of the solvent, the amino derivative 
(21) in 91 % yield. Finally, 21 was subjected to the transamination/oxidation 
reaction to afford the desired 1-aryl-5-aroyl tetrazoles. After an extensive 
screening, we identified the Rapoport procedure
58  
as the 
transamination/oxidation reaction able to give the best yields, allowing us to 
isolate, after acidic work up and column chromatography, the 1-aryl-5-aroyl 
tetrazoles derivative (22) in 50 % yield. (Scheme 15). 
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[a) : MeOH, rt, 48h; b) H2, Pd/C 10%, MeOH, 60°C, 24h; c) i) 4-formyl-1-methyl pyridinium 
benzene sulphonate, DCM/DMF 3:1, 8h; ii) TEA, 30 min; iii) oxalic acid aq. sln. 6h] 
Scheme 15. General procedure for the synthesis of 1-Aryl-5-Aroyl Tetrazoles.  
 
The Rapoport transamination/oxidation reaction represents a simple and mild 
biomimetic conversion of amines to carbonyls in the presence of 4-formyl-1-
methylpyridinium benzenesulfonate as pyridoxal phosphate (vitamin B6) 
surrogate. The amine and the formyl derivative were stirred in DCM/DMF 3:1 
for 8 hours at room temperature. Triethylamine was then added and 
deprotonation occured under mild conditions forming an azaenolate. After 
about 30 minutes, the resonance-stabilized anion was protonated and 
hydrolyzed with an aqueous solution of oxalic acid to give the 4-
(aminomethy)-1-methyl pyridinium salt and the desired carbonyl compound 
(Scheme 16). 
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Scheme 16. The Rapoport biomimetic transamination/oxidation. 
To demonstrate the scope and generality of this new synthetic strategy seven 
aldehydes (6, 18, 23-27), eight isocyanides (5, 19, 28-33) with different 
electron withdrawing and electron donor substituents were employed. The 
reaction was usually performed with unsubstituted benzylamine 17, but it was 
also tested with substituted benzylamines 34, 35 (Figure 10). 
 
Ugi-like 4-CR reaction was performed mixing the aldehyde, isocyanide, 
benzylamine and trimethylsilyl azide in methanol (2M), stirring at room 
temperature for three days. All MCR products (20, 36-51) were isolated in 
high yields (59-86 %) (Table 2). In case of isocyanide 28, the Ugi is 
performed with the O-protected tert-butyl-dimethylsilyl derivative 28a. The 
tert-butyl-dimethylsilyl was then cleaved under conditions reported in 
literature (for details see experimental section of the chapter).  
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Figure 11. Aldehydes (A), isocyanides (B) and benzylamines (C) building 
blocks. 
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Product Aldehyde Isocyanide Benzylamine Yield 
20 18 19 17 59% 
36 6 5 17 70% 
37 26 30 17 74% 
38 18 32 17 78% 
39 18 30 17 86% 
40 23 32 17 53% 
41 24 32 17 87% 
42 24 29 17 65% 
43 27 29 17 71% 
44 25 5 17 63% 
45 26 29 17 69% 
46 24 31 17 82% 
47 18 28a* 17 75% 
48 18 33 17 81% 
49 18 29 34 39% 
50 18 28a* 35 67% 
51 23 33 35 72% 
 
Table 2. Synthesized Ugi adducts.  
 
When the product was solid it was possible to obtain it just filtering the 
precipitate under vacuum, while, in the case of oily products, they were 
purified by chromatographic column using petroleum ether/EtOAc as eluent. 
Hydrogenolysis was carried out for 24 hours and the resulting primary amines 
(21, 52-64) were isolated by simple filtration in excellent yields (60-95 %) 
(Table 3). Finally, the amine derivatives were subjected to the biomimetic 
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transformation giving the desired 1-aryl-5-aroyl tetrazoles (22, 65-77) in 
moderate to good yields (38-61%) (Figure 6). 
 
 
Product Starting Ugi adduct Yield 
21 20 91% 
52 36 72% 
53 37 95% 
54 38 93% 
55 39 70% 
56 40 68% 
57 41 77% 
58 42 77% 
59 43 92% 
60 44 71% 
61 45 60% 
62 46 92% 
63 47 66% 
64 48 92% 
 
Table 3. Synthesized primary amines from benzyl hydrogenolytic cleavage.  
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Product Starting Ugi adduct Yield 
22 21 50% 
65 52 50% 
66 53 44% 
67 54 63% 
68 55 50% 
69 56 46% 
70 57 40% 
71 58 38% 
72 59 61% 
73 60 41% 
74 61 39% 
75 62 46% 
76 63 46% 
77 64 38% 
 
Table 4. Trans-amination final 1-aroyl-5-aryl-tetrazole adducts.  
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2.7 Medicinal chemistry interest of 1-Aryl-5-Aroyl Tetrazole 
derivatives as biomimetic of antitubulinic chalcones.  
A growing solid tumor needs a new developing vasculature for oxygen, 
nutrients, depuration, etc.
59
 If the developed vascular bed is disrupted or 
destroyed, the tumor stops its growing. The first proof of concept  that this 
idea could be feasible was provided when a ricin-conjugated antibody directed 
against  an endothelial protein was able to eradicate the tumoral mass in 
mice.
60 
Therapeutically it is possible to adopt two different strategies: 1) 
arresting the development of the growing tumoral vasculature and 2) 
destroying the already established vasculature perfusing the tumoral mass. It 
is demonstrated that it is possible targeting selectively the tumoral 
neovasculature endothelial cells over the normal vasculature, as they both 
express unique proteins. If we consider a plasma membrane protein expressed 
uniquely on the tumoral vasculature, we could envisage the use of specific 
antibodies conjugated with toxins, vaccines, etc. Yet it is possible that the 
neovasculature is more sensitive over normal tissues to more traditional small-
molecule drugs. Also this strategy has been exploited, and a number of 
compounds have entered or are entering clinical trials, referred as “low 
molecular weight vasculature-disrupting agents”. For example, the growth of 
the neovasculature is dependent on activation of the vascular endothelial 
growth factor receptor, and therefore, a number receptor antagonists have 
been devised and are currently tested or employed.
61
 Disruption of tubulin 
polymerization also disrupts the formation of tumoral vasculature, and it is 
therefore no surprise that a number of agents have been brought forward into 
drug pipeline that share this mechanism of action. 
The interest in 1-aryl-5-aroyl-tetrazole scaffold arose from its structural 
similarity with some antitubulinic chalcones as already shown in paragraph 
2.6. Chalcones are open-chain molecules consisting of two aromatic rings 
linked by a three-carbon enone fragment. It has been demonstrated that they 
can act as tubulin polymerization inhibitors by binding to the colchi-site of 
tubulin in a reversible manner (78, 79 Figure 12).
62
 To date, despite the 
interesting pharmacological properties demonstrated by this class of 
compounds, there are no chalcones as antitubulinic agents in clinic or pre-
clinic studies. This seems to be due to their metabolic instability in vivo. 
Indeed, the phenolic group can easily undergo phase II metabolism and the 
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enone system can undergo Michael additions with biological nucleophiles 
such as glutathione. 
 
 
Figure 12. Examples of chalcones 78 and 79 and their IC50s. 
 
Other drawbacks can be: a) chalcones are promiscuous structures with a 
plethora of biological activities; and b) they can have patentability problems. 
For these reasons, over the last decades, chalcones have been used as starting 
points to design and synthesize novel stable analogues with the same 
antimitotic effect and a better efficacy/safety window.
63
 In particular, 
modifications on the chalcone scaffold regarding the replacement of the 
double bond have been fulfilled maintaining cytotoxicity and antitubulin 
action, suggesting that the double bond is not strictly required for this 
biological activity (80-84) (Figure 13).
64
 Taking advantage of the possibility 
to replace the olefinic bond to set up rapid synthetic approaches that might be 
used to generate libraries based on the chalcone scaffold, we thought to 
substitute the double bond of chalcones with a tetrazole moiety, a 
metabolically stable and chemically inert heterocyclic ring (Figure 7).  
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Figure 13. Some literature reported modifications of chalcone scaffold.   
 
Preliminary molecular modelling studies were performed, superimposing 
chalcone structure 78 with scaffold 76 (Figure 14). Conformation of 78, 
docked into the colchi-site of tubulin, was used as reference and 
superimpositions were made by using the VegaZZ
65
 software. Visual 
inspection allowed us to see that tetrazole analogues can replace the double 
bond of chalcone, maintaining the correct alignment of the pharmacophoric 
groups (Figure 7).  To investigate the biological activity of the synthesized 
compounds, we opted for SH-SY5Y cells, a neuroblastoma cell line which we 
have previously shown to be sensitive to antitubulin agents (e.g. 
combretastatin, taxol).
66
 In brief, cells were treated for 48 hours with the 
selected compounds and viability was determined by the MTT method. In this 
cell line, chalcone 1 displayed an IC50 for cell death of 50 + 3 nM, confirming 
the choice of cellular model. All compounds were first screened at a 
concentration of 10 µM.. The tetrazole derivatives were also inactive except 
for compound 76 (Figure 14 and 15). We therefore proceeded with a 
concentration response curve of the active compounds under the same 
conditions (Figure 16). 76 displayed an IC50 for cell viability of 4.1 + 0.3 µM. 
To confirm the mechanism of action of these compounds, we performed a cell 
cycle analysis. It would be expected that antitubulin agents, by disrupting the 
mitotic spindle, induce a G2/M block. For these experiments, cells were 
treated for 16 hours at a concentration twice the determined IC50. As expected, 
chalcone induced a strong G2/M block, and this effect was reproduced when 
using compound 76.  
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Figure 14. Compound 76.  
 
 
 
 
Figure 15. MTT essay for compound 76.  
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Figure 16. Cell-cycle inhibition essays.  
 
In conclusion, replacement of the double bond with tetrazole has been 
considered for antitubulinic chalcones.
67
  Only one compound (76) retained 
activity, albeit displaying a very low potency compared to chalcone 78. This 
new scaffold has the advantage of being amenable to rapid synthesis via a 
multicomponent reaction and could therefore be envisaged to generate a large 
array of analogues. Yet, it should be noticed that the potency reported here for  
76 is in the same order of magnitude as other analogues previously reported 
which attempted to replace the olefinic bond, raising the question on whether, 
unlike combretastatin, the olefinic bridge on chalcones is not merely a 
structural linker. 
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3. Search for novel Multi-Component Reactions 
 
3.1 About the identification of novel MCRs 
While the use of a MCR followed by post-condensation modifications is a 
successful strategy  for the easy and fast access to usually elusive and 
challenging molecules, the identification of new Multi-Component Reactions 
is, however, a more difficult  and  interesting task. In this chapter will be 
presented the study of an interrupted Ugi reaction in order to obtain the 
morpholin-2-one scaffold that unlucky failed to reach good yields and 
remained undeveloped, and some small paragraphs on “substrate design” 
based projects. This concept is based on a multi-functionalized starting 
material which, when introduced in a known MCR, could undergo new and 
different transformations, deviating the reaction mechanism toward a new 
pathway.  
 
3.2 Morpholin-2-ones through an interrupted Ugi reaction  
Morpholin-2-ones are essentially δ-lactones and have been studied as amino 
acid analogues
1 
and as building blocks for pharmaceutically interesting 
compounds.
2
 They have been employed as conformationally more stable 
cyclic analogues of acyclic α-amino acids esters for asymmetric induction in 
the formation of amide bonds through aminolysis.
3
 The morpholinone 
skeleton has also been fully investigated as an effective template for 
asymmetric reactions
4 
and identified as calpain and thrombin inhibitor.
5
 
Anyway, in the last ten years, the great interest for this scaffold is to be 
ascribed to the development of Aprepitant, an antiemetic drug  acting as 
substance P antagonist (SPA). It mediates its effect by blocking the 
neurokinin 1 (NK1) receptor. Aprepitant is manufactured by Merck & Co. 
under the brand name Emend
®
 for prevention of acute and delayed 
chemotherapy-induced nausea and vomiting (CINV) and for prevention of 
postoperative nausea and vomiting. It was approved by the FDA in 2003.
6
  
The morpholine core plays a pivotal role in the aprepitant maintaining the 
correct allignement  of the pharmacophoric groups (Figure 1). Over the last 
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decades  there has been  a scientific effort to get an easy access to 
morpholinones intermediates allowing a more practical and less costly 
synthesis of Aprepitant.   
 
Figure 1. Aprepitant structure showing its morpholinone core.  
 
Basically, the morpholi-2-one scaffold is synthesized starting from N-benzyl-
2-amino alcohols and bromo esters
7
, or substituted phenylglycines and 
benzaldehyde, followed by N-alkylation with bromo ethane and a thermal 
cyclizations of the resulting N-benzyl-bromoethyl derivatives.
8
 Other methods 
reported in literature started with amide derivative of substituted N-benzyl-
glycine and bromo ethanol,
9
 or N-substituted amino ethanols and divinyl 
fumarate
10
 or, still, with ethentricarboxylic acid diesters (Figure 2).
11
 
All these methods are affected by problems of low yields, limitation in 
starting material availability, scope and/or scaling up processes.  
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Figure 2. Some literature reported procedures for the synthesis of morpholin-
2-ones.   
 
We therefore decided to find a novel synthetic method for the construction of 
morpholin-2-one using a multicomponent transformation. Disconnection of 
morpholin-2-one scaffold (1) shows us  that it might be synthesized by an 
interrupted Ugi reaction (Figure 3), where the nitrilium ion intermediate (2) is 
trapped intramolecularly by the hydroxyl group of N-benzylethanolamine 
(Scheme 1). (For general mechanism of Ugi 4-CR see Introduction). The 
mechanism is shown in Scheme 2. A Schiff base (5) , formed by an aldehyde 
(3) and N-benzylethanolamine (4) undergoes a nucleophilic addition mediated 
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by the isocyanide (6), to afford a nitrilium ion intermediate (2). This latter 
undergoes an intramolecular nucleophilic addition to the hydroxyl group of 
the N-benzylethanolamine, affording an imino ether derivative (7), which 
after hydrolisys of the imino function and elimination of an amine molecule 
bearing the isocyanide radical affords the desired morpholin-2-ones (1).  
 
 
Figure 3. Disconnection of morpholin-2-ones.  
 
 
 
Scheme 1. Mechanism of the exploited interrupted Ugi.   
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For the test reactions biphenyl-4-carboxaldehyde (8), N-benzylethanolamine 
(2) and tert-butyl-isocyanide (9) were chosen (Figure 5).  
 
 
Scheme 2. Test reaction for experimental conditions screening.   
 
The solvents were trifluoroethanol (TFE) (entry 1, 5-12), methanol (entry 2), 
water (entry 3) and toluene (entry 4), with TFE being the best one (entry 1). In 
some cases a weak acid (entry 4), Lewis acids (entry 5-11) or molecular 
sieves (entry 12) to facilitate the Schiff base formation were added, but no 
improvement in yields were observed.  In addition, an in situ reduction of the 
imino ether derivative (7, Figure 4) with sodium cyanoborohydride was 
attempted, but it still failed to increase the yield of morpholin-2-one. All the 
experimented conditions failed to afford the desired morpholin-2-one in more 
than 48%  yield (entry 1). 
 
Entry Solvent  Additive Yield 
1 TFE None 48% 
2 MeOH None 5% 
3 H2O None NP 
4 Toluene NH4Cl NP 
5 TFE Phenylacetic 
acid 
38% 
6 TFE Benzoic 
acid 
NP 
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7 TFE PTSA NP 
8 TFE MgSO4 
(2 eq RNC) 
40% 
9 TFE MgSO4 40% 
10 TFE MgSO4, 
then 
NaBH3CN 
41% 
11 TFE Na2SO4, 
then 
NaBH3CN 
NP 
12 TFE MS 4Å then 
NaBH3CN 
36% 
NP = not purified 
Table1. Experimental conditions. (Reaction time 24h ; room temperature) 
 
The idea of the in situ reduction arose from the observation of an open-chain 
by-product formed by hydrolysis of the imino ether derivative (7, Scheme 1). 
This intermediate, indeed, can undergo the desired elimination of tert-butyl 
amine (path A), but the tetrahedric intermediate can also follow a different 
fate (path B) to give an open chain amide 11 (Scheme 3). It is important to 
highlight that the ring-opening process is likely to be thermodynamically 
favorable due to formation of the stable amide bond.    
Very recently, Motherwell and Sheppard described the ring-expansion of 
oxazolidines 12 to morpholin-2-ones via reaction with an isocyanide followed 
by hydrolysis.
12
 The reaction conditions were improved using a design of 
experiments approach (DoE), being the factors investigated the acid catalyst 
(mol%), the isocyanide (equivalents) and solvent type. Anyway DoE 
investigation failed to yield the desired morpholin-2-ones in more than  51% 
yield (DMSO 0.5M as solvent, TsOH 1.1 eq. as acid catalyst, isocyanide 1 eq. 
heating to 75°C under an atmosphere of nitrogen for 24h) (Figure 4).  
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Scheme 3. Alternative pathways affording the desired morpholin-2-one and 
the amide side product 12. 
 
 
Figure 4. Oxazolidine ring-expansion investigated by Motherwell and 
Sheppard.   
 
Sorensen et al reported recently the synthesis of indoxyls and aminoindoles 
through an interrupted Ugi 3-CR.
13 
Other examples of morpholin-2-ones 
synthesized through MCRs were reported by Kim et al. in 2001 and by 
Motherwell and et al. in 2006. 
14,15
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3.3 Substrate design approach in search for novel MCRs 
In Jieping Zhu laboratories I worked on  the “substrate design approach” for 
the search of novel MCRs. The rationale of this approach is as follows: it 
consists of designing new poly-functionalized substrates for known MCRs 
that, when mixed with the other components, would react in a highly ordered 
manner and productive fashion to afford in high yield an interesting scaffold. 
The new function introduced on one of the MCR- substrates  would be able, 
indeed, to deviate the course of the reaction toward new pathways : in this 
way a novel MCR can be uncovered.
16
 In this context, Zhu et al. demonstrated 
that simply switching the ester function of α-isocyano acetate 13 to amide, the 
resulting isocyanoacetamide 14 displayed completely different reactivity 
profile as compared to 13 (Figure 5).
17 
  
 
  
Figure 5. Isocyano acetate and isocyano acetamide based MCRs.  
By taking advantage of the chemical reactivities of 5-amino oxazole and 
based on the three- component  synthesis of 5-amino oxazoles starting from 
isocyano acetamides, dozens of MCRs were developed by judicious selection 
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of reaction partners.
18 
Some representative heterocycles synthesized are 
showed in Figure 6.
 
Zhu et al. subsequently developed isocyanides 15  and 16 
 
 
(Figure 7) and MCRs thereof. 
19, 20
 
 
Figure 6. Some representative examples synthesized starting from isocyano 
acetamides 14. 
 
 
Figure 7. Other examples of  synthesized isocyanides for the development of 
new “substrate design approach” based MCRs.   
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Investigation and synthesis of N-isocyanobenzamide 17 (Figure 8) is thus a 
logical extension of the “substrate design approach” herein presented. To 
better understand the design of this isocyanide you have to compare it with 
compound 18, which presents the same framework of isocyano acetamide 14 
with the methylene group replaced by a nitrogen to give a N-isocyano-N,N’-
disubstituted urea. Zhu’s group already tried to synthesize 18, but it lacked in 
stability to be easy handled and isolated. If we observe structure 18 not as an 
urea but as an isocyano acetamide 14 with a NH function instead of a CH2, we 
could  think  that changing  the CONHR1 of 18 into a COR framework could 
enhance the stability of such a molecule.  
 
 
Figure 8. New functionalized isocyanide investigated by Zhu.     
 
The disconnection of 17 shows that it could be synthesize in three steps 
starting from benzoic acid coupling with hydrazine, formylation of this 
derivative and dehydration of N-formyl function to isocyanide (Figure 9). 
 
Figure 9. Disconnection of 17.  
 
Monoacylation of  hydrazine was achieved in 92% yield starting from ethyl 
benzoate 19 as reported in literature,
21
 affording benzohydrazide 20 that, after 
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purification by flash chromatography was refluxed in formic acid for 30 
minutes
22
 to give N-formyl benzohydrazide 21 (100% conversion) (Scheme 4). 
 
 
Scheme 4. Synthesis of  N-formyl benzohydrazide 21.  
 
Different dehydration conditions were then tested on compound 21 in order to 
obtain the desired   isocyanide 17, ranging from the classical POCl3/TEA or 
COCl2/TEA systems
23
 at different temperatures (-78°C, -5°C) to less 
conventional and milder method as the one employing Burgess reagent (-78°C, 
-50°C, -18°C, rt and 50°C).
24
 Burgess reagent or methyl N-
(triethylammoniumsulfonyl) carbamate 22 (Scheme 5) is an inner salt used as 
mild and selective dehydrating reagent to convert secondary and tertiary 
alcohols with an adjacent proton into alkenes, primary amides into nitriles, 
formamides into isocyanides and it is also employed in the synthesis of some 
heterocycles.
25
 One of its great advantage is to be orthogonal with other 
functional groups which are often problematic in the presence of the common 
dehydrating agents. Its mechanism of action involves as first step the 
formation of a sulfamate ester 23, where the part then acting as leaving group 
has been incorporated. This part has multiple H
+
 acceptor sites, lowering the 
free energy of the process owing to an increased positive entropy  contribution. 
Second step is  therefore a hydrogen transfer followed by elimination of 
methoxycarbonyl sulfo-amide 24. Anyway, all the dehydrating experimented 
conditions only afforded the cyclizations adduct  2-phenyl-1,3,4-oxadiazole 
25 plus starting material depending on the reaction conditions (Scheme 6). In 
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order to compare chromatographic and spectroscopic data of compound 
yielded by different dehydration test reactions, compound 25 was synthesized 
as reported in literature (P2O5, toluene, reflux, 2.5h).
26
 All the compared data 
perfectly matched.  
 
 
Scheme 5. Mechanism of action of Burgess reagent.  
 
 
 
Scheme 6. Dehydration of 21 only afforded 2-phenyl-1,3,4-oxadiazole 25.  
 
Hypothesizing that,  under dehydrating conditions , as soon as the isocyanide 
was formed, or not even formed, it cyclized to the more stable 1,3,4-
oxadiazole derivative 25, we tried to get the desired compound through a ring-
opening strategy hoping that at very low temperatures the open-chain 
isocyanide form would be enough stable to exist. Even if oxazoles  ring-
opening is something already reported in literature, ring-opening strategy for 
the synthesis of functionalized isocyanides starting from oxazoles was 
described for the first time by Pirrung et al. in 2006.
27
 Oxazoles 26 are readily 
metalated by treatment at -78°C in THF with n-BuLi at the 2-position 
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(Scheme 7). The resulting anion 27 equilibrates (by α-elimination/ring-
opening) with α-isocyano enolate 28. With oxazoles and benzoxazoles the 
latter form predominates and has been observed by NMR.
28
 Trapping of 28 by 
O-Acylation with an acyl chloride gives product such as 29 (Scheme 4). 
 
 
Scheme 7. Oxazole ring-opening strategy described by Pirrung et al.  
 
Despite different test reactions performed, this strategy, when applied to 
oxadiazoles (Scheme 8), failed to afford the O-Acylated isocyanide 30, giving 
back starting material and traces of an unidentified product. When the reaction 
was performed at -18°C, with 1.05 equivalents of n-BuLi, a dimer with the 
proposed structure 31 was isolated (Figure 10).
29
 A possible scenario 
accounting for the formation of 31 is shown in Scheme 9. Herein 25 is readily 
metalated at 4 position, giving the lithiated derivative 32, which is then 
reacting with acetyl chloride added in situ to give 33. A second molecule of 
32 could then undergo a nucleophilic addition into 33 to give dimer 31. If 30 
could be isolated, then an O-acyl cleavage could be attempted in order to get 
17. We are not able to state if the α-isocyano enolate was formed or not or 
also if it was formed and the equilibrium is biased toward the ring-closed 
metalated oxadiazole. Structural investigation of the equilibrium between 2-
Lithium oxazole, thiazole and imidazole derivatives and their acyclic isomers 
showed that  the tendency of these compounds to undergo ring-opening 
parallels the leaving group properties of the various subunits 
[ROLi˃RSLi˃R2NLi].
30
 To date, there is no metalated oxadiazole ring-
opening described. The project was  therefore abandoned. 
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Scheme 8. Oxadiazole ring-opening strategy tested in order to get compound 
17. 
 
Figure 10. Proposed dimer structure  for a side product obtained during one 
of ring-opening test reactions.     
 
 
Scheme 9. Proposed mechanism for the formation of 31. 
 
Following the same “substrate design approach” synthesis of isocyanides 34, 
35 and 36 was investigated (Figure 11). 
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Figure 11. Designed isocyanides  34, 35 and 36.    
 
As disconnection of 34 we thought to devise a three steps sequence starting 
from aniline (with or without a halogen group in the ortho position), 
formylating it, dehydrating the formyl derivative and then metalating the 
aromatic ring in the ortho position so that trapping with an electrophile could 
be possible  (Figure 12).  
 
 
Figure 12. Retro-synthetic pathway of 34.     
 
The iodo derivative 37 is described to undergo fast trans-metallation reactions 
when treated with n-BuLi or t-BuLi at very low temperatures (-78°C and -
100°C). Trapping of the resulting ortho-lithiophenyl isocyanide 38 with 
different electrophiles (iodine, methyl chloroformiate, diphenyl sulfide, 
methyl formiate amd others) has been described allowing the synthesis of 2-
substituted isocyanides 39; when the electrophile is an isocyanates or an 
isothiocyanate 3H-quinazolin-4-ones and 3H-quinazolin-4-thiones 40 were 
formed in high yields (Scheme 10).
31
 α-metallated isocyanides 41 are known 
since Schöllkopf and Gerhart
32
 first exploited in 1968 how the electron-
withdrawing effect of the isocyano group enhances the acidity of the α-C-H 
bonds (Figure 13). Since then, α-metallated isocyanides have been shown to 
participate in various types of co-cyclizations leading to different nitrogen 
containing heterocycles.
33
 In 1977 Ito, Saegusa
34
 et al. described γ-metallated 
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43 isocyanide: ortho-methylphenyl isocyanide metalated at the benzilic 
positions has been reported to underwent cyclizations to indoles. β-metallated 
isocyanides 42 have been reported for the first time in 1978 by Walborsky.
 35
 
First reaction investigated was a halogen-metal exchange of o-iodo-phenyl 
isocyanide 37 synthesized starting from the aniline derivative as reported in 
literature
31 
in order to trap the deriving ortho-lithio isocyanide 38 with a 
carbodiimide (for test reaction we used commercially available diisopropyl 
carbodiimide, DIC 44). Two different cyclizations adducts were isolated 45 
and 46, being the former N-(3-isopropylquinazolin-4(3H)-ylidene)propan-2-
amine and the latter the alkylated 2-butyl derivative in a 3/1 ratio (Scheme 11). 
The formation of the cyclization adduct probably is to be ascribed to the 
reaction mechanism, where, after the attack of the metalated isocyanide 38 β-
carbon into the carbodiimide 44 electrophilic carbon atom, a negatively 
charged  nitrogen containing intermediate 47 was formed. This latter could be 
then able to attack the isocyanide carbon atom here acting as electrophile to 
give intermediate 48. This can then be quenched by moisture or aqueous 
work-up to afford the quinazoline 45. A working hypothesis for the formation 
of the 2-alkylated derivative 46 is quenching of 45 by the in situ generated 
butyl iodide after the halogen-lithium exchange (Scheme 12). Reaction with 
the more bulky and less nucleophile tert-Butyllithium, which cannot generate 
tert-butyl iodide, and quenching (of the presumable intermediate 47) with 
both NH4Cl and acetic anhydride failed as well to give the desired compound 
34.  
 
 
Scheme 10. Reaction of ortho-lithiophenyl isocyanide with electrophiles 
described by de Mejere. 
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Figure 13.α,β and γ-metallated isocyanides.   
 
 
Scheme 11. Reaction of 38 with DIC affording 53 and 46.  
 
 
Scheme 12. Possible scenario for the formation of 45 and 46.  
 
In order to avoid the formation of the cyclized adduct 48, we tried an 
alternative approach and we started from N-phenyl formamide 50 (in order to 
try after dehydration of 49)  and N-Boc protected aniline 51 (tert-butyl phenyl 
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carbamate) (in order to de-protect 52 to 51, and transform then the amine 
function in isocyanide through the conventional formylation/dehydration 
sequence)(figure 14).  
 
 
Figure 14. Additional disconnection approaches  for the synthesis of 34.  
 
Reaction of 50 with different equivalents (2.2 and 2.4) of t-BuLi and n-BuLi, 
in THF at -78°C, followed by in situ addition of carbodiimide 44 failed to 
afford the desired isocyanide 34, but degradation, formation of unidentified 
dimers and recovering of the starting materials were observed. Direct ortho 
functionalization was however possible when 44 was reacted with lithiated 54 
to afford 55 (Scheme 13).
36
 This reaction requires 2.4 equivalents of 
alkyllithium reagent as a dianion 54 is formed. In this reaction the NH-Boc 
group acts as Directed Metallation Group (DMG) for Directed ortho 
Metallation (DoM).
37 
NH-Boc group belongs to the class of Heteroatom-based 
DMGs and was described for the first time as that by Muchoswki in 1980.
36
 
There is no unifying mechanism for the DoM reaction that can explain all the 
subtleties observed experimentally. The most widely accepted one can be 
summarized in three steps (Scheme 14). A rapid equilibrium between 
alkyllithium aggregates and a prelithiation complex of the alkyllithium 
coordinated to the DMG 56. In this complex the base is in close proximity to 
the ortho proton which allows the slow but irreversible proton abstraction 
forming the coordinated ortho-lithiated species 57. Addition of an electrophile 
provides in the simplest cases the regioselective formation of a 1,2-
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disubstituted arene 58. The initial hypothesis for this mechanism was dubbed 
by Klumpp as the Complex-Induced Proximity Effect (CIPE).
38
  
 
 
Scheme 13. Formation of 55.  
 
 
 
Scheme 14. CIPE mechanism for DoM.  
 
Test reactions with 50 failed to afford the desired adduct 49 probably because 
the formyl group is not a good DMG. To date it has never been described as 
DMG, and as Snieckus stated a good DMG “must exhibit the somewhat 
schizophrenic properties of being a good coordinating site for alkyllithium 
67 
 
and a poor electrophilic site for attack by this strong base”.37 It is possible to 
imagine that the formyl group could be attacked by the alkyllithium and start 
different side reactions giving an intractable mixture.  
Last test reaction was the ring-opening of 45 with n-BuLi in THF at -78°C 
followed by addition of TMSCl to trap the open-chain lithium isopropyl 
amide  60  in equilibrium with the ring-closed metalated  derivative 59. Only 
the ring-closed silyl derivative 61 was observed (98% conversion) (Scheme 
15).
39
 The project was so abandoned.  
 
 
Scheme 15. Ring-opening test reaction of 45.  
 
Synthesis of 35 could be possible in two steps starting from N-hydroxy 
benzimide acid 63, through conversion of this latter in N-hydroxy 
benzimidoyl chloride 62 and then substitution with silver cyanide (AgCN) 
(Figure 15). 
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Figure 15. Disconnection of 35.   
 
Chlorooxime 62 was synthesized as reported by Dubrovskiy and Larock.
40 
Its 
synthesis is very fast and simple: in practice benzaldehyde, hydroxylamine 
hydrochloride and Na2CO3 were refluxed in water for two hours. After basic 
work-up, the residue was dissolved in chloroform and a drop of pyridine was 
added. After 5 minutes N-chlorosuccinimide was added portion-wise and the 
mixture was stirred overnight. 62 is enough stable to be purified by flash 
chromatography. Chloride substitution was attempted in dry DCM at room 
temperature and at 40°C (entry 1 and 2, table 2) with commercially available 
silver cyanide, but only starting material was recovered. Reaction with freshly 
prepared silver cyanide in dry DCM at room temperature (entry 3) was 
unsuccessful as well. Other test reaction conditions (entry 4-6) were 
experimented using ammonium salts 64 and 65 as phase-transfer catalysts 
(Figure 16).
41
  
 
Figure 16. Phase-transfer catalysts tested for the synthesis of 35.   
 
Entry Salt Temperature Catalyst 
1 AgCN (C) rt no 
2 AgCN (C) 40°C no 
3 AgCN (FP) rt no 
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4 AgCN (FP) plus KCN 40°C 64 
5 AgCN (FP) plus KCN 40°C 65 
6 AgCN (FP) plus TMSCN 40°C 64 
C= commercial; FP= freshly prepared.  
Table 2. Test reactions for the synthesis of 35.    
 
None of the tested reactions was able to give the desired isocyanide 35. 
Before abandoning the project, 1,3,5-oxadiazole 66 ring-opening reaction 
with n-BuLi and in situ trapping with TMSCl was unsuccessfully attempted 
(Scheme 15).
42 
As previously observed for compound 45, only ring-closed 
trimethyl silylated derivative 67 was detected by 1H-NMR of the crude.
43
 In 
conclusion all test reactions failed to yield the desired isocyanide 35. 
 
 
Scheme 15. 1,3,5-phenyloxadiazole 66 ring-opening test reaction.    
 
Disconnection of 36 suggest that it could be synthesized in two steps starting 
from N-phenyl benzamide 69, passing through N-phenyl benzimidoyl 
chloride or bromide 68, and trying a substitution with silver cyanide (Figure 
17). 
 
Figure 17. Disconnection of 36. 
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Synthesis of 36 is reported by Höfle and Lange
44 
 in 1977 and synthesis of 68 
by a Bayer Patent of 1973.
45
 Anyway, first attempts to  get the imidoyl 
bromide 68 (X= Br)  revealed to be  difficult, with reaction showing a 
degration pattern on TLC. A deepened search in literature revealed that Ta-
Shma and Rappoport
46
 in 1977 wrote about them: ” imidoyl bromides were 
stable when kept at 0°C in the dark and argon atmosphere. On dissolution in 
polar solvents (e.g. “dry” acetonitrile) a very rapid hydrolysis to the 
benzanilides took place.“ As the first requirement for an isocyanide starting 
material is a ready accessibility, and this was not the case, the project was 
abandoned.  
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4. Between old and new: project in progress and future 
perspectives 
 
4.1 The project in progress: an introduction.  
While I am writing this thesis, the last project of my PhD research program is 
on-going in Zhu laboratories. This project involves a new MCR sequence, 
namely an Ugi/Aza-Wittig using the N-isocyanoiminotriphenylphosphorane 1 
as key reagent (Figure 1) to afford the 1,3,4-oxadiazoles of general structure 2.  
 
 
Figure 1. N-isocyanoiminotriphenylphosphorane 1.   
Compound 1 is commercially available and also easily accessible 
synthetically in good yields, as described by Bio et al., as a thermally stable 
off-white crystalline solid.
1
 
 
As shown in Scheme 1, 1 was obtained from 
reaction of commercially available formic hydrazide 3 with PPh3 and CCl4 
using DBU as base.  
 
 
Scheme 1. Synthesis of 1as reported by Bio et al.   
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1 has already been described for the synthesis of α-diazoketones and different 
N-containing heterocycles (Figure 2) as 2-aryl-1,3,4-oxadiazoles, 2-aryl-5-
hydroxyalkyl-1,3,4-oxadiazoles, oxadiazepine derivatives, triazolo[4,3-
c]quinazolines derivatives.
2-6 
In the course of our investigation into the 
Ugi/Aza-Wittig sequence to give 2-aryl-5-aminoalkyl-1,3,4-oxadiazoles, the 
reaction was described by Iranian chemists.
7 
 
 
Figure 2. Literature reported compounds synthesized starting  from 1.   
 
In all the reported examples 1 reacts first with its isocyanide moiety to give a 
nitrilium ion that underwent a further attack by a nucleophile (as for 
compounds 2,6-8), followed by an intramolecular aza-Wittig reaction (except 
for compound 4). 
The intramolecular Aza-Wittig reaction has been recently reviewed with 
several carbonyl or analogous compounds.
8
 In those reactions both 
phosphazene moiety and carbonyl-oxygen double bond (C=O) (aldehydes, 
ketones, esters, amides, anhydrides...) are present in the same molecule a 
(Figure 3). This strategy allows for a simple and effective method for the 
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preparation from five- to different size N-containing heterocyclic compounds 
b in very mild reaction conditions (apolar solvents, absence of catalysts, mild 
reflux or room temperature). Substitution on the phosphorus atom in 
phosphazene moiety with different alkyl groups could increase its reactivity 
decreasing the positive charge on the phosphorous atom and increasing the 
negative charge on nitrogen. According to Scheme 4 the reaction takes place 
via a tandem [2+2] cycloaddition-cycloreversion through a thermally allowed 
supra-supra mechanism, with 9 as  a quite stable intermediate and transition 
states TS1 and TS2.  
 
Figure 3. General scheme of intramolecular Aza-Wittig reaction.  
 
 
Scheme 4. Mechanism of Aza-Wittig reaction.  
 
Our interest in oxadiazoles  arose from the possibility to perform, once an 
alkyne moiety will be introduced on this scaffold, an intramolecular Diels-
Alder reaction. In this scenario, the oxadiazole ring acts as diene, to afford 
different condensed bicylo-furans 14, 15, 20 (Scheme 5). Two different 
strategies for the introduction of the alkyne functional group were therefore 
approached: one using the amines 10 and 11 with a methyl or ethyl linker, so 
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that the Ugi adduct will already have incorporated the dienophile (A, Figure 4 
and Scheme 5) and the second performing an in-situ amidation with a 
propargyl acid derivative (such as chloride 17 or activated ester 18), after an 
Ugi reaction with a primary amine (B, Figure 4 and Scheme 5).  
 
Figure 4. Approaches for the project in progress.   
 
Scheme 5. Approaches for the project in progress.   
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4.2 Background of the project: Zhu’s oxazoles chemistry. 
The project is following a typical strategy performed in Zhu’s laboratories. In 
2001 he first published a three component synthesis of 5-amino-oxazoles 21 
and their subsequent reaction with α,β-unsaturated acyl chlorides leading to 
polysubstituted pyrrolopyiridines 22.
9 
When the reaction was performed in 
toluene in the presence of ammonium chloride, it was possible to get the 
desired compound 22 in a one-pot fashion.
10
 A triple domino process, 
acylation/IMDA/retro-Michael cycloreversion, was involved in the described 
synthesis.  
 
Figure 5. 5-Amino-oxazoles 21 and pyrrolopyridine 22 described by Zhu.  
 
In the individuation of this strategy Zhu was inspired by the possibility to 
expand the potential of MCR chemistry with its proper union with other 
sequential or domino processes for the complexity-generation/ diversity-
oriented synthesis of drug-like compounds libraries.  Compound 21 was 
obtained via a 3-CR starting from an aldehyde 23, an amine 24 and an 
isocyano acetamide 25 in very mild reaction conditions and high yields. 
Heating then a solution of 21 and acid chloride 26  in toluene at reflux 
temperature led to formation of 22 in good yields (Scheme 6).  
 
 
Scheme 6. Domino process for the synthesis of 22.  
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The proposed scenario for the reaction is the formation of amide 27 which 
undergoes intramolecular Diels-Alder reaction affording the bridged tricyclic 
intermediate 28. Base-catalyzed retro-Michael cycloreversion then furnished 
22 (Scheme 7). The coupling constants between Ha and Hb (JHa-Hb= 4.1 Hz) 
indicated a gauche relationship (dihedral angle around 40°) between these two 
protons. For the inherent ring strain imposed by the connecting bridge, only 
the lactam-exo-ester-endo mode of cycloaddition was possible, leading to the 
observed compound 28. In this intermediate, the proton Hb is properly aligned 
with Cc-O bond, which facilitates the difficult 5-endo-trig  reversal leading to 
22 and morpholine 29.  
 
Scheme 7. Proposed mechanism for acylation/IMDA/retro-Michael 
cycloreversion.  
 
Another example of how  a 5-aminooxazole can be a chemical platform to get 
polysubstituted N-containing heterocycles is the one-pot 3-CR of an ortho-
amino cinnamate 30, α-isocyano acetamide 31 and an aldehyde 32, giving 33, 
that underwent an intramolecular Diels-Alder cycloaddition to give oxa-
bridged tetracyclic tetrahydroquinolines 34 (Scheme 8).
11 
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Scheme 8. Synthesis of oxa-bridged tetracyclic tetrahydroquinolines.  
 
Again, changing the aniline from 30 to 35 affords furo[2,3-c]quinolines 39 
always in a multicomponent domino fashion.
12
 Reaction sequence is based on 
an intramolecular cycloaddition between the aza-diene oxazole 36 with a 
properly disposed triple bond to give an oxa-bridged heterocycle 37. This 
latter, after extrusion of the nitrile unit by a retro Diels-Alder reaction, would 
provide the furan 38, which undergoes oxidation by atmospheric oxygen to 
furnish furoquinolines 39.  
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Scheme 9. Reaction mechanism for the synthesis of 39.  
 
Continuing to exploit the potential of 5-aminooxazoles 21 Zhu described as 
well the synthesis of hexasubstituted benzenes 40 combining three component 
synthesis of oxazoles with two subsequent cycloaddition-based domino 
processes, which means in total a five component reaction.
13
 Also in this case 
the sequence allows for a rapid and efficient construction of structurally 
complex molecules from readily available starting materials. Reaction of 21 
and acyl chloride 41 provide the amide 42 that undergoes in a domino fashion 
a first  intramolecular Diels-Alder cycloaddition, through intermediate 43, to 
5,6-dihydro-furo[2,3-c]pyrrol-4-one 44 and, after addition of one more 
dienophile 45 a retro Diels-Alder cycloaddition to yield , through 46, 
hexasubstituted benzene 40 as shown in Scheme 10.  
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Scheme 10. One-pot five component synthesis of hexasubstituted benzenes 40. 
 
When the dienophile was introduced in the 5-amino-oxazole as the starting 
amine 47, then a fast and easy access to polysubstituted 4,5,6,7-
tetrahydrofuro[2,3-c]pyridines 50 had been provided (Scheme 11).
14 
47, 31 
and 32 reacted to give first the 5-aminooxazole 48 and subsequentely an 
intramolecular Diels-Alder gave oxa-bridged intermediate 49, which 
underwent fragmentation by a retro Diels-Alder to final compounds 50. So, 
simply heating a solution of the three components in toluene, in the presence 
of ammonium chloride afforded the desired 50 in a one-pot domino fashion in 
high yields.  
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Scheme 11. One-pot three component synthesis of 50 described by  Zhu et al.  
 
A more recent application of the chemistry of 5-aminooxazoles as chemical 
platform describes the employment of methyl α-(p-nitrophenyl)-α-isocyano 
acetate 51 (Scheme 12).
15
 As previously, 52 is yielded by a 3-CR between 51, 
23 and 24. The resulting secondary amine 52 is then acylated to 53 through 
addition of an opportune chloride. The  introduced dienophile allowed an 
intramolecular Diels-Alder to get the oxa-bridged intermediate 54. A retro 
Diels-Alder reaction of 54 finally afforded the furopyrrolones 55.   
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Scheme 12. One-pot four component synthesis of 55. 
 
4.3 The project in progress: results and discussion.  
For the synthesis of compounds 14 and 15, amines 10 and 11 were 
synthesized in order to obtain 12 and 13. Before optimizing the one-pot 
procedure, a multi-step synthesis was performed in order to figure out the best 
reaction conditions. Amine 11 was synthesized as reported by Momose et al. 
(Scheme 13).
16 
Amine 11 was synthesized in four steps starting from but-3-yn-1-yl-
methylbenezenesulfonate 56  and benzylamine 57 to get compound 58.
17
 The 
secondary amine 58 is then protected with a tert-butoxycarbonyl group in 
order to derivatize the terminal alkyne function of 59 with an alkyl lithium 
reagent and ethyl chloroformate. Finally 60 Boc protecting group was cleaved 
with a classical procedure to afford 11. More problematic was the synthesis of 
amine 10 (Scheme 14). To our knowledge 10 is not described in literature, 
while a possible undesired adduct during the synthesis of 10 has been  
identified in Zhu’s laboratories.18 
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Scheme 13. Synthesis of amine 11. 
 
 
Scheme 14. Synthesis of amine 10.  
 
Analogously to amine 11, amine 10 is synthesized in four steps starting from 
3-bromo-prop-1-yne 61  and benzylamine 57 to get in a nucleophilic 
substitution 62. The secondary amine 62 is then protected with a tert-
butoxycarbonyl group in order to derivatize the terminal alkyne function of 63 
with an alkyl lithium reagent and ethyl chloroformate. Finally 64 Boc 
protecting group is cleaved with a classical procedure to afford 10. For the 
first three steps the yield are quite good, while the cleavage of Boc group was 
low yielding (52%) because of side reactions and low stability of product. 
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Synthesis of amine 65 (Figure 6) has previously been attempted in Zhu’s 
laboratories, following an analogous procedure. During the cleavage of the 
Boc group of 66, however, only 2-oxazolidinone 67 was recovered (Scheme 
15), with yields ranging from 68% to 98% depending on deprotection reaction 
conditions. From classical procedures at different temperatures (TFA/DCM, 
HCl/AcOEt) to less conventional ones, employing TMSOTf ,  2,6-lutidine and 
DCM have been screened. The cyclization of N-Boc-protected alkynlamines 
into the corresponding alkylidene 2-oxazolidinones has been reported in 
literature by Carretero et al.
19
 as a gold catalyzed reaction(AuPPh3Cl, 5 mol%; 
AgSbF6 5 mol%, DCM, rt). The gold catalysis allows for very short reaction 
times (5 minutes for yields up to 95%). The mechanism is shown in Scheme 
16:  it involves the nucleophilic attack of the carbamate carbonyl group on the 
activated Au(I)-alkyne complex 68 to afford the cationic vinyl-gold 
intermediate 69. Subsequent tert-butyl fragmentation, likely by releasing 
isobutene and a proton, would give rise the oxazolidinone-Au complex 70, 
which after protonation would provide the observed  oxazolidinone 71. An 
analogous mechanism could be envisaged to account for the formation of 67, 
without the gold-mediated activation of the alkyne function (Scheme 17). In 
this case, 66 alkyne function would be already enough electrophilic to be 
attacked by the carbamate oxygen atom to give intermediate 72 bearing a 
negative charge. This latter would further undergo t-butyl cleavage and 
protonation to 67.  
 
 
Figure 6. Amine 65.  
 
 
 
Scheme 15. Obtainment of 67 from 66 cleavage.  
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Scheme 16. Carretero gold catalyzed 2-oxazolidinones  formation mechanism.  
 
 
 
Scheme 17. Proposed mechanism for the formation of 67. 
 
Ugi reaction performed with amines 10 and 11, isovaleraldehyde 73, 
isocyanide 1 and para-toluic acid 74 afforded the desired Ugi adducts 75 and 
76 in 28% and 39% yields, respectively (A and B, Scheme 18). Low yields 
could be ascribed to a low reactivity of the amine, that is, a low availability of 
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the Schiff-base in the reaction  mixture in DCM. Between 30%  and 40% of 
Passerini/Aza-Wittig adduct 77 was indeed isolated in both Ugi-reactions, 
meaning that the isocyanide, the aldehyde and the acid prefer reacting in a 
Passerini/ Aza-Wittig fashion (Figure 7). Anyway different test reactions to 
increase the yield of the Ugi adduct are still in progress.  
 
 
 
Scheme 18. Test Ugi/Aza-Wittig reactions with amines 10 and 11.  
 
 
 
Figure 7. Passerini/ Aza-Wittig adduct 77 isolated from Ugi/Aza-Wittig test 
reactions with amine 10 and 11.  
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Intra-molecular Diels Alder cyclizations of 75 and 76 to 78 and 79 (Scheme 
19) are actually under investigations, screening different solvents and 
temperatures. After heating 76 under microwave conditions at 210 °C for 28 h 
compound 79 has been detected in quite low yields, encouraging anyway 
further optimization of reaction conditions. Probably higher temperatures are 
requested to allow the cyclization to be faster and minimize formation of side-
products. Compound 75 was instead heated at 180 °C until disappearance of 
the starting material (4 d). In this case, the reaction profile seems to be much 
more complex, as a new unpredicted major product (not showed) was 
obtained. A full characterization of this latter, and studies about its 
reproducibility are in progress.   
 
Scheme 19. Attempted Intra-Molecular Diels-Alder cyclizations on substrate 
75 and 76.  
 
Dealing with the synthesis of furo-pyrrolones 20, in order to identify best 
conditions for the one-pot procedure, optimization of single-step reaction 
conditions was attempted. It is important to highlight that the central step of 
the one-pot procedure, that is, the amidation of the secondary nitrogen of the 
Ugi/Aza-Wittig adduct 16 (Scheme 5),  is allowed by the use of a primary 
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amine in the former multi-component reaction (Figure 4). Focusing on the 
Ugi/Aza-Wittig sequence, a deep analysis of the reaction mechanism shows 
that with primary amines, in theory, two pathways are likely. Once the imine 
80 is formed in situ, and the isocyanide 1 has been added to it, the carboxylate 
undergoes a nucleophilic addition into the nitrilium ion 81, to give 
intermediate 82. This latter could stand two different transformations.  The 
first one follows  the classical Ugi reaction mechanism with Mumm 
rearrangement of intermediate 82 followed by the Aza-Wittig reaction of 
intermediate 83 affording triazinone derivatives 84 (path A, Scheme 20). The 
second one (path B, Scheme 20) does not involve the Mumm rearrangement, 
to give directly the intramolecular Aza-Wittig reaction on 82 affording 
oxadiazoles derivatives 85. It is important to remember that the Mumm 
rearrangement in the Ugi reaction is the key irreversible step of the reaction 
allowing the obtainment of the Ugi adduct in high yields (For details on Ugi 
reaction mechanism see Introduction). In the paper concerning the Ugi/Aza-
Wittig sequence by Ramazani and Rezaei
7
, only secondary amines have been 
described. In our test reaction (DCM, rt, 20h)   with 2-phenethyl amine 86, 
aldehyde 73, isocyanide 1 and acid 74, we were pleased to find that the four 
components Ugi/Aza-Wittig reaction with primary amines allowed the 
obtainment of the desired oxadiazol 87 in 70% yield (Scheme 21) suggesting 
that the Aza-Wittig reaction is kinetically favored over the Mumm 
rearrangement.  
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Scheme 20. Reaction mechanism of Ugi/Aza-Wittig sequence with primary 
amines: in theory two different pathways are likely. 
 
 
Scheme 21. Test reaction with primary amine 86 giving the desired 
oxadiazole 87.  
 
Taking a closer look at compound 77, an analogous reasoning could explain 
its formation. We can consider it, indeed, as a product deriving from the 
combination of 73, 1 and 74 in a Passerini-like reaction. According to the 
classical mechanism of Passerini reaction intermediate 89, given by the α-
addition of the carboxylate 74 into the nitrilium ion 88, should undergo an O-
acyl transfer to give 90 (path A, Scheme 22), followed by the intramolecular 
Aza-Wittig reaction yielding oxadiazinone derivatives 91. Anyway no traces 
of 91 were detected, but only 77 was obtained demonstrating again that the 
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intramolecular Aza-Wittig reaction is faster, that is kinetically favored over 
the O-acyl transfer (path B, Scheme 22). These reaction pathways could also 
be ascribed to the higher stability of five-membered fully conjugated 
oxadiazoles 77 and 85 over triazinone 84 and oxadiazinone 91 suggesting a 
likely concomitantly thermodynamic control influencing the reaction.  
 
 
Scheme 22. Reaction mechanism for the synthesis of 6: two different 
pathways are likely in theory. 
 
Once the Ugi/Aza-Wittig adduct with primary amines 87 was established, we 
investigated the amidation reaction. Addition of  triethylamine and  3-
phenylpropriolyl chloride 17 (Scheme 5) to purified 87 afforded amide 92 in 
67% yield (Scheme 23). Formation of a double-acylation unknown side 
product was observed and minimized by performing the reaction at 0°C for 
two hours.  
94 
 
 
Scheme 23. Amidation reaction of 87. 
 
Finally, stirring purified 92 overnight in a high-boiling solvent such as ortho-
dichlorobenzene, afforded, by means of an intra-molecular diaza-Diels-Alder 
cyclization (IMDDA)/ retro-Diels-Alder sequence, furopyrrolone 93 in  87% 
yield (Scheme 24).  
 
Scheme 24. Intra-molecular Diels-Alder cyclization of 92.  
 
 A possible scenario accounting for its formation is depicted in Scheme 25. 
The dienophile, the triple bond introduced in the amidation reaction, reacts 
with the 3,4-diaza diene moiety of the oxadiazole in a [4+2] cycloaddition to 
afford the oxa-bridged intermediate 94. This latter undergoes a retro-Diels-
Alder process favored by loss of nitrogen to give 93. A test reaction with 
substrate 95 (Scheme 26), in the identical reaction conditions of 93, failed to 
afford the Diels-Alder adduct 96 suggesting that the presence of electron-
withdrawing substituents on the dienophile moiety could be important. This 
could be in agreement with a normal Diels-Alder reaction where the overlap 
between the highest occupied molecular orbital of the diene (HOMO) and the 
lowest unoccupied molecular orbital (LUMO) of the dienophile is thermally 
allowed. In this case electron-withdrawing groups can decrease the energy of 
the LUMO, and the diene component should be as electron-rich as possible so 
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that the provided molecular orbitals would be of similar energy. Anyway a 
more detailed study of our IMDA is requested to understand its nature. The 
Diels-Alder reaction of oxadiazoles is indeed usually described as an inverse 
electron demand Diels-Alder, where the diene acts as the LUMO and the 
dienophile provides the HOMO.
20
 Vasilev,
21
 Sauer,
 22
 Seitz
23
 and Warrener
24
 
described examples of the participation of electron-deficient and typically 
symmetrical 1,3,4-oxadiazoles 97 in an intermolecular reaction cascade with 
electron-rich or strained olefins providing 2:1 cycloadducts (Scheme 27). The 
reaction with such alkenes proceed by an initial inverse demande Diels-Alder 
reaction to provide a cycloadduct 98 that loses N2 to generate a carbonyl ylide 
99 that in turn further reacts with the alkene in a 1,3-dipolar cycloaddition to 
give 100. Boger et al. in 2002 reported for the first time intramolecular Diels-
Alder and tandem intramolecular Diels-Alder cycloaddition reactions of 1,3,4-
oxadiazoles.
25   
 
 
Scheme 25. Proposed mechanism for the Intra-Molecular Diels-Alder of 92.  
 
 
Scheme 26. Test reaction of 95 failed to afford Diels-Alder adduct 96.  
 
96 
 
 
Scheme 27. Inter-molecular Diels-Alder reaction of electron deficient 1,3,4-
oxadiazoles and with electron-rich olefins.  
 
4.4 Conclusions and future perspectives. 
To be able to combine the investigated single steps (MCR/Amidation/IMDA) 
or (MCR/IMDA) an appropriate choice of the solvent is crucial. As for the 
IMDA a high boiling solvent such as ortho-dichlorobenzene (o-DCB) is 
requested, next step toward the optimization of the one-pot procedure was 
performing the Ugi/Aza-Wittig MCR in such a solvent. To our delight 
Ugi/Aza-Wittig MCR affording 85 (Scheme 20) in o-DCB and ammonium 
chloride
26
 gave oxadiazole derivatives in comparable yields while MCR with 
amines 10 and 11 remained to be optimized. Amidation reaction on purified 
oxadiazole 85 in  o-DCB seemed to work as nice as in DCM. A full-sequence 
MCR/Amidation/IMDA one-pot reaction for the obtainment of 93 (Scheme 
24) is now under investigations. The project in progress aims to demonstrate 
that 1,3,4-oxadiazoles, as already reported for oxazoles, could be a chemical 
platform for the synthesis of a wide range of N-containing multi-
functionalized heterocycles. The Ugi/Aza-Wittig reaction with primary 
amines and the observation of a non-competitive Mumm rearrangement 
opened to interesting mechanistic considerations about the reaction pathway. 
The Intra-Molecular Diels-Alder reaction of oxadiazole 92 (Scheme 23) 
raised an intriguing question about its nature. The study of stronger or weaker 
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electron-withdrawing group on the dienophile moiety could be, e.g., a useful 
approach to get new insights. Last but not least, IMDA with oxadiazole 75 
failed to yield the desired dihydro-furopyrrol 78 affording an unexpected 
major adduct which needs to be  fully characterized. Studies on the 
reproducibility of the reaction as well are in progress. IMDA of oxadiazoles 
76 successfully gave  the desired tetrahydro-furopyrrole 79, but yields remain 
to be further improved.  
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General informations. 
 
Commercially available reagents and solvents were used without further purification and 
were purchased from Fluka-Aldrich or Lancaster. Melting points were determined in open 
glass capillary with a Stuart scientific SMP3 apparatus and are uncorrected. All the 
compounds were checked by IR (FT-IR THERMO-NICOLET AVATAR); 1H and 13C 
APT (JEOL ECP 300 MHz) and mass spectrometry (Thermo Finningan LCQ-deca XP- 
plus) equipped with an ESI source and an ion trap detector. Chemical shifts are reported in 
part per million (ppm). Column chromatography was performed on silica gel (Merck 
Kieselgel 70-230 mesh ASTM) using the indicated eluants. Thin layer chromatography 
(TLC) was carried out on 5 x 20 cm plates with a layer thickness of 0.25 mm (Merck Silica 
gel 60 F254).When necessary they were developed with KMnO4. Elemental Analysis of 
all the 1-aryl-5-aroyl tetrazoles (C, H, N) are within ± 0.4 % of the calculated values unless 
otherwise noted. Isocyanides (5, 19, 28-33) are described in literature. We synthesized 
them in two steps starting from the aromatic anilines, forming the formamide and 
dehydrating it with POCl3. 
 
1-(ethylamino)-1-oxobutan-2-yl 2-iodobenzoate (2). Procedure: to a solution of  
heptanal (1 eq) in DCM (1M), 2-iodobenzoic acid (1eq) and  1-pentyl isocyanide (0.05g, 
0.515 mmol), were added  and stirred overnight. After completion of the reaction, the 
reaction mixture was evaporated and purified by silica gel chromatography (Petroleum 
ether/ AcOEt 4:1, Rf = 0.3), yield 69%. 1H-NMR (300 MHz, CDCl3)  δ 7.97 (d, J= 9 Hz, 
1-H), 7.79 (d, J= 9 Hz, 1-H), 7.42 (t, J= 15 Hz, 1-H),  7.17 (t, J= 15 Hz, 1-H), 6.31 (bs, 
NH), 5.38 (t, J= 12 Hz, 1-H), 3.29-3.22 (m, 2-H), 2.00-1.92 (m, 2-H), 1.52-1.22 (m, 14-H), 
0.85-0.81 (m, 6-H); 13C-NMR (75 MHz, CDCl3) δ 168.88, 164.97, 140.93, 134.47, 
132.61, 130.77, 127.71, 93.21, 75.25, 38.82, 31.50, 31.14, 28.75, 28.58, 28.48, 24.44, 
22.07, 21.85, 13.57, 13.52. C13H16INO3 
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General procedure for the preparation of 1-aryl-5-aroyl tetrazoles. 
 
Equimolar amounts of aromatic isocyanide, aromatic aldehyde, N-benzylamine and 
trimethylsilylazide were dissolved in dry methanol (2M) under a nitrogen atmosphere. The 
resulting solution was stirred at room temperature for three days. The solid formed was 
filtered off and washed with cold methanol. For oily products, the reaction mixture was 
evaporated and purified by column chromatography using PE/EtOAc as eluants. The 
obtained tetrazole intermediate was then stirred in methanol under a hydrogen atmosphere 
in the presence of Pd/C 10 % heating at 60 °C for 24 h. The crude reaction was filtered 
through a Celite pad and evaporated to give the free amine enough pure for the following 
step. The amine was dissolved in CH2Cl2/DMF 3:1 and 4-formyl-1- methylpyridinium 
benzenesulfonate (1.2 eq) was added. The reaction mixture was stirred at room 
temperature for 8 h, then treated with triethylamine (1.0 eq) and stirred for 15-20 min. The 
reaction was finally quenched with a cold saturated aqueous solution of oxalic acid and 
stirred overnight. The reaction was then diluted with water and CH2Cl2. After extraction 
with CH2Cl2 (x3) the combined organic phases were washed with brine (x1), dried over 
sodium sulphate, filtered, and evaporated under reduced pressure. The carbonyl compound 
was purified by column chromatography using PE/AcOEt as eluant. 
 
N-benzyl-1-(1-(4-methoxyphenyl)-1H-tetrazol-5-yl)-1-(3,4,5- 
trimethoxyphenyl)methanamine (20). The crude material was filtered under vacuum, 
washed with cold methanol and evaporated to give a white solid (59 %). IR (KBr) 3290, 
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2943, 1591, 1323, 1256, 1131, 834 cm
-1
; 1H-NMR (300 MHz, CDCl3)  δ 7.24-7.23 (m, 5-
H), 7.01 (d, J= 9 Hz, 2-H), 6.87 (d, J= 9 Hz, 2-H), 6.35 (s, 2-H), 4.88 (s, 1-H), 3.82 (s, 3-
H), 3.78 (s, 3-H), 3.72 (s, 8-H); 13CNMR (75 MHz, CDCl3) δ 161.5, 160.4, 156.3, 155.5, 
152.8, 137.9, 137.2, 127.8, 127.7, 126.7, 126.4, 125.3, 124.1, 113.9, 103.9, 60.1, 55.5, 
55.41, 55,0 , 50.5; MS (ESI) m/z 462 (M+H)
+
; Mp = 112-116°C. C25H27N5O4 
 
 
 
N-benzyl-1-(1-(4-methoxyphenyl)-1H-tetrazol-5-yl)-1-(3,4,5- 
trimethoxyphenyl)methanamine (36) The crude material was purified by column 
chromatography, using petroleum ether/EtOAc 6:4 as eluant to give a yellowish oil (70 %). 
IR (KBr) 3288, 2326, 1275, 1128, 749, 764 cm
-1
; 1H-NMR (300 MHz, CDCl3) δ 7.12-
7.04 (m, 5-H), 7.01 (d, J= 9 Hz, 2-H), 6.70 (d, J= 9 Hz, 2-H), 6.23 (s, 2-H), 4.93 (s, 1-H), 
3.75 (s, 3-H), 3.764 (s, 3-H), 3.55 (s, 8-H); 13C-NMR (75 MHz, CDCl3) δ 159.1, 155.8, 
153.0, 138.8, 138.5, 128.6, 127.9, 127.7, 126.7, 113.7, 102.6, 60.4, 55.7, 54.9, 54.7, 50.5; 
MS (ESI) m/z 462 (M+H)
+
. C25H26N5O4. 
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N-benzyl-1-(biphenyl-4-yl)-1-(1-(4-phenoxyphenyl)-1Htetrazol-5-yl)methanamine (37). 
The crude material was purified by column chromatography, using petroleum ether/EtOAc 
8:2 as eluant to give a brown oil (74 %). IR (KBr) 3291, 2360, 2341, 1521, 1237, 733, 788, 
699 cm
-1
; 1H-NMR (300 MHz, CDCl3) δ 7.59-6.97 (m, 23-H), 5.12 (s, 1-H), 3.80 (s, 2-H); 
13C-NMR (75 MHz, CDCl3) δ 159.5, 156.4, 155.8, 141.5, 140.3, 138.9, 137.0, 130.3, 
129.0, 128.6, 128.5, 128.4, 127.7, 127.2, 124.8, 120.0, 118.7, 55.6, 51.2; MS (ESI) m/z 510 
(M+H)
+
. C33H27N5O. 
 
 
 
1-(1-(benzo[d][1,3]dioxol-5-yl)-1H-tetrazol-5-yl)-N-benzyl-1-(3,4,5,-trimethoxyphenyl) 
methanamine (38) The crude material was filtered under vacuum, washed with cold 
methanol and evaporated to give a pale yellow solid (78 %). IR (KBr) 3278, 2925, 1502, 
1323, 1131, 894, 747 cm
-1
; 1H-NMR (300 MHz, CDCl3) δ 7.25-7.23 (m, 5-H), 6.78 (d, J = 
9 Hz 1-H), 6.61-6.56 (m, 2-H), 6.41 (s, 2-H), 6.05 (s, 2-H), 4.89 (s, 1-H), 3.79 (s, 3-H), 
3.75 (s, 6- H), 3.72 (s, 2-H); 13C-NMR (75 MHz, CDCl3) δ 156.3, 153.6, 149.5, 148.4, 
138.7, 138.1, 133.4, 128.6, 128.5, 127.5, 127.0, 119.8, 108.4, 106.9, 104.9, 102.5, 60.9, 
56.4, 56.3, 51.3; MS (ESI) m/z 476 (M+H)
+
; Mp = 123-126 °C. C25H25N5O5.  
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N-benzyl-1-(1-(4-phenoxyphenyl)-1H-tetrazol-5-yl)-1-(3,4,5,- 
trimethoxyphenyl)methanamine (39). The crude material was filtered under vacuum, 
washed with cold methanol and evaporated to give a pale yellow solid (86 %). IR (KBr) 
3420, 1617, 1509, 1242, 1132, 700 cm
-1
; 1H-NMR (300 MHz, CDCl3) δ 7.36-6.92 (m, 16-
H), 6.38 (s, 2-H), 4.92 (s, 1-H), 3.76 (s, 2-H), 3.71 (s, 3-H); 13C-NMR (75 MHz, CDCl3) δ 
159.6, 156.4, 155.6, 153.6, 138.9, 138.1, 133.4, 130.3, 128.6, 128.5, 127.9, 127.5, 127.4, 
124.9, 120.0, 118.4, 104.9, 60.9, 56.3, 56.2, 51.2; MS (ESI) m/z 524 (M+H)
+
; Mp = 126-
130 °C. C30H29N5O4. 
 
 
 
5-((1-(benzo[d][1,3]dioxol-5-yl)-1H-tetrazol-5-yl)(benzylamino)methyl)-2-
methoxyphenol (40). The crude material was purified by column chromatography, using 
petroleum ether/EtOAc 6:4 as eluant to give a colourless oil (53 %). IR (KBr) 3290, 2361, 
1505, 1246, 1270, 1033, 743, 730, 699, cm
-1
; 1H-NMR (300 MHz, CDCl3) δ 7.22-7.16 (m, 
5-H), 6.79 (d, J = 3Hz, 1-H), 6.73 (s, 1-H), 6.70 (s, 1-H), 6.64 (dd, Jo,m= 9Hz, 6Hz, 1-H), 
6.54 (m, 1-H), 6.51(d, J = 3Hz, 1-H), 5.99 (s, 2-H), 4.86 (s, 1-H), 3.78 (s, 3-H), 3.67 (s, 2-
H); 13C-NMR (75 MHz, CDCl3) δ 156.6, 149.6, 148.6, 147.2, 146.4, 138.9, 131.0, 128.6, 
128.6, 127.5, 127.0, 119.7, 119.6, 114.5, 111.2, 108.5, 106.8, 102.6, 60.6, 56.2, 55.5, 51.2; 
MS (ESI) m/z 432 (M+H)
+
. C23H21N5O4. 
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1-(1-(benzo[d][1,3]dioxol-5-yl)-1H-tetrazol-5-yl)-N-benzyl-1-(4-chlorophenyl)-methan 
amine (41). The crude material was purified by column chromatography, using petroleum 
ether/EtOAc 8:2 as eluant to give a colourless oil (87 %). IR (KBr) 3283, 1505, 1244, 1035, 
811, 732, 699 cm
-1
; 1H-NMR (300 MHz, CDCl3) δ 7.20-7.12 (m, 9-H), 6.68 (dd, Jo,m= 
12Hz, 6Hz, 1-H), 6.54-6.48 (m, 3-H), 5.96 (s, 2-H), 4.93 (s, 1-H), 3.62 (s, 2-H); 13C-NMR 
(75 MHz, CDCl3) δ 156.2, 149.6, 148.7, 138.8, 136.7, 134.5, 129.5, 129.2, 128.9, 128.5, 
127.5, 126.9, 119.7, 108.5, 106.7, 102.7, 60.5, 55.2, 51.2; MS (ESI) m/z 420 (M+H)
+
. 
C22H18ClN5O2. 
 
 
 
N-benzyl-1-(4-chlorophenyl)-1-(1-phenyl-1H-tetrazol-5-yl)- methanamine (42). The 
crude material was purified by column chromatography, using petroleum ether/EtOAc 9:1 
as eluant to give a colourless oil (65 %). IR (KBr) 3295, 1492, 1091, 1015, 702, 762, 736, 
691 cm
-1
; 1H-NMR (300 MHz, CDCl3) δ 7.46-7.34 (m, 3-H), 7.23-7.09 (m, 11-H), 4.99 (s, 
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1-H), 3.67 (s, 2-H); 13C-NMR (75 MHz, CDCl3) δ 156.5, 139.2, 137.1, 134.9, 133.9, 
131.3, 130.3, 129.9, 129.6, 129.5, 129.1, 128.9, 128.4, 127.9, 125.9, 55.7, 51.6; MS (ESI) 
m/z 389 (M+H)
+
. C21H18ClN5. 
 
 
 
N-benzyl-1-(4-morpholinophenyl)-1-(1-phenyl-1H-tetrazol-5-yl)methanamine (43). 
The crude material was filtered under vacuum, washed with cold methanol and evaporated 
to give an off-white solid (71 %). IR (KBr) 3238, 2812, 1513, 1263, 1112, 921, 699 cm
-1
; 
1H-NMR (300 MHz, CDCl3) δ 7.40-7.29 (m, 3-H), 7.17-7.05 (m, 8-H), 6.73 (d, J= 9Hz, 
2-H), 4.89 (s, 1-H), 3.69 (t, J= 9Hz, 4-H), 3.62 (s, 2-H), 3.01 (t, J= 9Hz, 4-H); 13C-NMR 
(75 MHz, CDCl3) δ 157.2, 151.9, 139.7, 134.2, 131.2, 130.4, 129.4, 129.1, 129.1, 127.9, 
126.0, 116.2, 67.4, 55.9, 51.7, 49.5; MS (ESI) m/z 450 (M+Na)
+
; Mp= 89-93°C. 
C25H26N6O. 
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N-benzyl-1-(2-(3-methoxyphenyl)-2H-tetrazol-5-yl)-1-(3,4,5-trimethoxyphenyl) 
methanamine (44). The crude material was purified by column chromatography, using 
petroleum ether/EtOAc 6:4 as eluant to give a yellow oil (63 %). IR (KBr) 3288, 1592, 
1460, 1235, 1124, 729, 688 cm
-1
; 1H-NMR (300 MHz, CDCl3) δ 7.20-7.12 (m, 6-H), 6.97 
(dd, Jo,m = 12Hz,6Hz, 1-H), 7.69 (dd, Jo,m = 9Hz,6Hz, 1-H), 6.60 (t, , J= 3Hz, 1-H), 6.36 (s, 
2-H), 4.92 (s, 1- H), 3.73 (s, 3-H), 3.67 (s, 8-H), 3.64 (s, 3-H); 13C-NMR (75 MHz, 
CDCl3) δ 161.3, 157.1, 154.5, 139.8, 138.9, 135.4, 134.4, 131.4, 129.5, 129.3, 128.3, 
118.6, 117.6, 112.2, 105.8, 61.7, 57.4, 57.1, 56.6, 52.2; MS (ESI) m/z 462 (M+H)
+
. 
C25H27N5O4. 
 
 
 
N-benzyl-1-(biphenyl-4-yl)-1-(2-phenyl-2H-tetrazol-5-yl)methanamine (45). The crude 
material was purified by column chromatography, using petroleum ether/EtOAc 8:2 as 
eluant to give a colourless oil (69 %). IR (KBr) 3286, 1597, 1453, 1101, 1008, 761, 733, 
692 cm
-1
; 1H-NMR (300 MHz, CDCl3) δ 7.57- 7.16 (m, 18-H), 5.11 (s, 1-H), 3.76 (s, 2-H); 
13C-NMR (75 MHz, CDCl3) δ 157.0, 142.1, 141.0, 139.6, 137.7, 134.2, 131.4, 130.5, 
129.7, 129.3, 129.2, 129.1, 128.6, 128.4, 128.4, 128.1, 127.8, 126.1, 56.3, 51.9; MS (ESI) 
m/z 418 (M+H)
+
. C27H23N5. 
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N-benzyl-1-(4-chlorophenyl)-1-(1-(4-morpholinophenyl)-1Htetrazol-5-yl)methan 
amine (46). The crude material was purified by column chromatography, using petroleum 
ether/EtOAc 6:4 as eluant to give a yellow oil (82 %). IR (KBr) 3290, 1521, 1450, 1236, 
1120, 926, 823, 699 cm
-1
; 1H-NMR (300 MHz, CDCl3) δ 7.24-7.12 (m, 9-H), 6.92 (d, J= 
9Hz, 2-H), 6.77 (d, J= 9Hz, 2-H), 4.94 (s, 1-H), 3.75 (m, 4-H), 3.62 (s, 2-H), 3.13 (m, 4-H); 
13CNMR (75 MHz, CDCl3) δ 156.8, 153.2, 139.5, 137.6, 134.9, 130.1, 129.7, 129.3, 
129.1, 128.1, 127.1, 124.8, 115.8, 67.3, 55.9, 51.8, 48.9; MS (ESI) m/z 461 (M+H)
+
. 
C25H25ClN6O. 
 
 
 
5-((benzylamino)(1-(3,4,5-trimethoxyphenyl)-1H-tetrazol-5-yl)methyl)-2-methoxy 
phenol (47). The crude material was filtered under vacuum, washed with cold methanol 
and evaporated to give a yellow solid (75 %). IR (KBr) 3284, 2835, 1509, 1465, 1232, 
1133, 999 cm
-1
; 1H-NMR (300 MHz, CDCl3) δ 7.25-7.12 (m, 5- H), 6.77 (s, 1-H), 6.68 (d, 
J = 9Hz, 1-H), 6.59 (dd, Jo,m= 12Hz, 6Hz, 1-H), 6.29 (s, 2-H), 4.89 (s, 1-H), 3.85 (s, 3-H), 
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3.77 (s, 3-H), 3.66 (s, 6-H), 3.36 (s, 2-H); 13C-NMR (75 MHz, CDCl3) δ 156.8, 154.1, 
147.7, 146.9, 139.9, 139.3, 131.4, 129.2, 129.1, 128.9, 127.9, 120.1, 115.1, 111.6, 103.7, 
61.6, 56.9, 56.6, 56.2, 51.6, 51.0; MS (ESI) m/z 478 ; Mp = 130-134 °C. C25H27N5O5. 
 
 
 
N-benzyl-1-(3-methoxyphenyl)-1-(1-(3,4,5-trimethoxyphenyl)-1H-tetrazol-5-yl) 
methanamine (48). The crude material was purified by column chromatography, using 
petroleum ether/EtOAc 7:3 as eluant to give a colourless oil (81 %). IR (KBr) 3286, 1508, 
1232, 1131, 1126, 735, 698 cm
-1
; 1H-NMR (300 MHz, CDCl3) δ 7.07-7.01 (m, 5-H), 6.66-
6.60 (m, 3-H), 6.22 (s, 2-H), 4.93 (s, 1- H), 3.68 (s, 3-H), 3.59 (s, 2-H), 3.55 (s, 3-H), 3.49 
(s, 6-H); 13C-NMR (75 MHz, CDCl3) δ 160.6, 156.6, 154.1, 140.2, 140.0, 139.4, 130.5, 
128.9, 128.8, 127.8, 120.7, 114.5, 114.1, 103.9, 61.4, 60.8, 56.8, 56.7, 55.8, 51.6; MS (ESI) 
m/z 475 (M+H)
+
. C25H27N5O4. 
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N-(4-methoxybenzyl)-1-(2-phenyl-2H-tetrazol-5-yl)-1-(3,4,5-trimethoxyphenyl) 
methanamine. (49) The crude material is purified by column chromatography, using 
petroleum ether/EtOAc 5:5 as eluant to give a yellowish amorphous solid (39%). IR 
1464.32, 1240.65, 1132.24, 763.90, 694.09 cm
-1
; 1H-NMR (300 MHz, CDCl3)  7.48-7.35 
(m, 3-H), 7.12-7.05 (m, 4-H), 6.70 (d, J= 9Hz, 2-H), 6.29 (s, 2-H), 4.86 (s, 1-H), 3.70 (s, 3-
H), 3.67 (s, 3-H), 3.66 (s, 3-H), 3.62 (s, 3-H), 3.59 (s, 2-H); 13C-NMR (75 MHz, CDCl3)  
159.60, 156.91, 154.17, 138.60, 134.26, 134.10, 131.45, 131.29, 130.26, 126.32, 114.55, 
105.39, 61.44, 56.79, 55.95,  51.26; MS (ESI) m/z 462.8  (M+H)
+
. C25H27N5O4. 
 
 
 
1-(2-(3-(tert-butyldimethylsilyloxy)-4-methoxyphenyl)-2H-tetrazol-5-yl)-1-(4-methoxy 
phenyl)-N-(3,4,5-trimethoxybenzyl)methanamine.  (50a) The crude material is purified 
by column chromatography, using petroleum ether/EtOAc 6:4 as eluant to give a yellowish 
amorphous solid (67%). IR 2933.50, 1516.82, 1241.77, 1131.93, 948.40, 840.71 cm
-1
;
 
1H-
NMR (300 MHz, CDCl3)  7.05 (d, J= 9Hz, 2-H), 6.79-6.72 (m,3-H), 6.63 (dd, Jo,m = 
9Hz,6Hz, 1-H), 6.52 (d,  J= 3Hz, 1-H), 6.39 (s, 2-H), 4.89 (s, 1-H), 3.77 (s, 3-H), 3.72 (s, 
6-H), 3.71 (s, 3-H), 3.68 (s, 2-H), 0.84 (s, 9-H), 0.01 (s,3-H), 0.00 (s, 3-H); 13C-NMR (75 
MHz, CDCl3)  160.44, 157.20, 154.04, 153.53, 146.37, 137.86, 135.51, 131.03, 129.82, 
126.73, 119.52, 118.77, 115.10, 112.52, 105.95, 61.57, 56.89, 56.44, 56.22, 56.05, 52.28, 
26.35,  19.14, -3.90, -3.95; MS (ESI) m/z 620.3  (M-H)
-
. C32H43N5O6Si 
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2-methoxy-5-(5-((4-methoxyphenyl)(3,4,5-trimethoxybenzylamino)methyl)-2H-
tetrazol-2-yl)phenol.  (50) The crude material is purified by column chromatography, 
using petroleum ether/EtOAc 6:4 and then 2:8 as eluant to give a yellowish oil (67%). IR 
1509.25, 1459.95, 1247.86, 1124.82, 731.79, 764.17 cm
-1
;
 
1H-NMR (300 MHz, CDCl3)  
7.11 (d, J= 9Hz, 2-H), 6.78-6.74 (m,3-H), 6.69 (d, J= 3Hz, 1-H), 6.51 (dd, Jo,m = 9Hz,6Hz, 
1-H), 6.42 (s, 2-H), 4.92 (s, 1-H), 3.83 (s, 3-H), 3.75 (s, 3-H), 3.73 (s, 9-H), 3.71 (s, 2-H); 
13C-NMR (75 MHz, CDCl3)  160.48, 157.22, 154.05, 149.37, 147.43, 137.87, 135.35, 
130.78, 129.84, 127.13, 117.82, 115.13, 112.98, 111.52, 106.06, 61.63, 56.99, 56.91, 56.14, 
56.03, 52.30; MS (ESI) m/z 506.27 (M-H)
-
. C25H29N5O6 
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5-((benzylamino)(1-(3,4,5-trimethoxyphenyl)-1H-tetrazol-5-yl)methyl)-2-methoxy 
phenol. (51) The crude material is purified by column chromatography, using petroleum 
ether/EtOAc 3:7 as eluant to give a light yellow solid (72%). IR 2838.31, 1474.75, 1326.79, 
1251.55, 1024.47, 879.43 cm
-1
;
 
1H-NMR (300 MHz, CDCl3)  7.26 (t, J= 15Hz, 1-H), 6.95 
(dd, Jo,m = 12Hz,6Hz, 1-H), 6.78 (d, J= 3Hz, 1-H), 6.70-6.66 (m, 3-H), 6.63 (s, 1-H), 6.40 
(s, 2-H), 4.88 (s, 1-H), 3.75 (s, 3-H), 3.73 (s, 3-H), 3.70 (s, 6-H), 3.64 (s, 3-H), 3.60 (s, 2-
H); 13C-NMR (75 MHz, CDCl3)  161.30, 157.16, 154.17, 147.98, 147.20, 137.94, 135.49, 
135.23, 131.85, 131.39, 120.40, 118.09, 117.63, 115.33, 111.89, 111.67, 106.13, 61.78, 
61.41, 57.03, 56.93, 56.52, 56.41, 52.45; MS (ESI) m/z 507.9  (M+H)
+
. C26H29N5O6. 
 
 
 
(1-(4-methoxyphenyl)-1H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl)methanamine (21). 
Yellow-brown solid (91%). IR (KBr) 3372, 3290, 2359, 1517, 1257, 1122, 834, 764 cm
-1
; 
1H-NMR (300 MHz, CD3OD)  7.01 (d, J= 9Hz, 2-H), 6.84 (d, J= 9Hz, 2-H), 6.26 (s, 2-
H), 5.14 (s, 1-H), 3.75 (s, 3-H), 3.68 (s, 3-H), 3.62 (s, 6-H); 13C-NMR (75 MHz, CD3OD) 
 160.4, 156.9, 152.8, 137.1, 134.8, 126.4, 126.1, 125.2, 113.9, 103.2, 60.0, 55.8, 55.3, 
50.6; MS (ESI) m/z 372 (M+H)
+
; Mp = 123-125°C. C18H21N5O4. 
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(4-methoxyphenyl)(1-(3,4,5-trimethoxyphenyl)-1H-tetrazol-5-yl)methanamine (52). 
White solid (72 %). IR (KBr) 3335, 3276, 2999, 1601, 1242, 1128, 1002, 848 cm-1; 1H-
NMR (300 MHz, CD3OD)  7.12 (d, J= 9Hz, 2-H), 6.81 (d, J= 9Hz, 2-H), 6.35 (s, 2-H), 
5.24 (s, 1-H), 3.86 (s, 3-H), 3.76 (s, 3-H), 3.68 (s, 6-H); 13C-NMR (75 MHz, CD3OD)  
159.1, 153.1, 138.9, 128.3, 127.9, 113.9, 102.7, 60.5, 55.8, 54.9, 50.4; MS (ESI) m/z 394.2 
(M+Na)
+
; Mp = 132-135°C. C18H21N5O4. 
 
 
 
biphenyl-4-yl(1-(4-phenoxyphenyl)-1H-tetrazol-5-yl)methanamine (53). White solid 
(95 %). IR (KBr) 3420, 3330, 2852, 1588, 1240, 1166, 1008, 758 cm-1; 1H-NMR (300 
MHz, CD3OD)  7.64-7.56 (m, 3-H), 7.47-7.14 (m, 8-H), 6.99-6.94 (m, 3-H), 6.12 (s, 1-H); 
13C-NMR (75 MHz, CD3OD)  159.9, 155.8, 152.8, 143.4, 139.4, 130.4, 129.9, 129.1, 
128.8, 127.9, 127.7, 127.2, 126.7, 124.4, 119.4, 118.5, 49.8, 48.5; MS (ESI) m/z 420 
(M+H)
+
; Mp = 234-236°C. C26H21N5O. 
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(1-(benzo[d][1,3]dioxol-5-yl)-1H-tetrazol-5-yl)(3,4,5,-trimethoxyphenyl)methanamine 
(54) White solid (93 %). IR (KBr) 3323, 3280, 2901, 1425, 1463, 1252, 1119, 1002, 860 
cm
-1
; 1H-NMR (300 MHz, CD3OD)  6.90 (d, J = 9 Hz 1-H), 6.78 (dd, Jo,m = 9Hz,6Hz, 
1-H), 6.70 (s, 1-H), 6.46 (s, 2-H), 6.06 (s, 2-H), 5.41 (s, 1-H), 3.71 (s, 6-H), 3.68 (s, 3-H); 
13C-NMR (75 MHz, CD3OD)  157.6, 153.5, 149.7, 148.5, 138.1, 134.3, 126.9, 120.2, 
108.2, 106.8, 104.9, 102.8, 59.9, 55.5, 51.0; Mp = 95-98 °C. MS (ESI) m/z 386 (M+H)
+
; 
Mp = 234-236°C. C18H19N5O5. 
 
 
 
(1-(4-phenoxyphenyl)-1H-tetrazol-5-yl)(3,4,5,-trimethoxyphenyl)methanamine (55). 
White solid (70 %). IR (KBr) 3370, 3280, 2838, 1512, 1462, 1244, 1125, 1009, 839 cm
-1
; 
1H-NMR (300 MHz, CD3OD)  7.42-6.98 (m, 9-H), 6.47 (s, 2-H), 5.64 (s, 1-H), 3.69 (s, 6-
H), 3.67 (s, 3-H); 13C-NMR (75 MHz, CD3OD)  171.7, 159.7, 156.5, 155.8, 153.6, 138.3, 
130.1, 127.9, 127.7, 124.6, 119.7, 118.4, 105.1, 60.3, 59.9, 55.5; Mp = 75-79 °C. MS (ESI) 
m/z 434 (M+H)
+
. C23H23N5O4. 
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5-(amino(1-(benzo[d][1,3]dioxol-5-yl)-1H-tetrazol-5-yl)methyl)-2-methoxyphenol (56) 
Dark yellow amorphous solid (68 %). IR (KBr) 3368, 3300, 2602, 1852, 1508, 1256, 1028, 
931, 890 cm
-1
; 1H-NMR (300 MHz, CD3OD)   6.89-6.83 (m, 2-H), 6.73-6.59 (m, 4-H), 
6.06 (s, 2-H), 5.56 (s, 1-H), 3.80 (s, 3-H); 13C-NMR (75 MHz, CD3OD)  155.7, 150.0, 
148.9, 148.8, 147.1, 128.0, 126.6, 119.9, 119.5, 114.6, 111.9, 108.3, 106.5, 102.9, 55.4, 
50.2; MS (ESI) m/z 342 (M+H)
+
. C16H15N5O4. 
 
 
 
1-(1-(benzo[d][1,3]dioxol-5-yl)-1H-tetrazol-5-yl)(4-chlorophenyl)methanamine (57) 
Off-white solid (77 %). IR (KBr) 3350, 3255, 2851, 1491, 1225, 1107, 893, 697 cm
-1
; 1H-
NMR (300 MHz, CD3OD)  7.41-7.38 (m, 2-H), 7.22-7.26 (m, 2- H), 6.86 (d, J = 9 Hz, 1-
H), 6.72-6.67 (m, 2-H), 6.05 (s, 2-H), 6.01 (s, 1-H); 13C-NMR (75 MHz, CD3OD)  152.9, 
150.2, 148.9, 131.8, 130.6, 129.5, 128.6, 126.2, 119.8, 108.3, 106.3, 102.9, 50.0; MS (ESI) 
m/z 330 (M+H)
+
; Mp = 238-241 °C. C15H12ClN5O2. 
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(4-chlorophenyl)(1-phenyl-1H-tetrazol-5-yl)-methanamine (58). Off-white solid (77 %). 
IR (KBr) 3300, 3278, 2853, 1560, 1458, 1258, 1075, 759, 530 cm
-1
; 1H-NMR (300 MHz, 
CD3OD)  7.59-7.19 (m, 9-H), 5.98 (s, 1-H); 13C-NMR (75 MHz, CD3OD)  153.9, 136.4, 
133.5, 133.3, 131.5, 130.7, 130.4, 130.3, 129.9, 128.8, 125.8, 50.1; MS (ESI) m/z 286 
(M+H)
+
; Mp = 229-232°C. C14H12ClN5. 
 
 
 
(4-morpholinophenyl)(2-phenyl)-2H-tetrazol-5-yl)methanamine (59). Yellowish oil (92 
%). IR (KBr) 3367, 3296, 2360, 1515, 1231, 1118, 925, 749 cm
-1
; 1H-NMR (300 MHz, 
CD3OD)  7.54-7.46 (m, 3-H), 7.27 (d, J= 6 Hz, 2-H), 7.02 (d, J= 9 Hz, 2-H), 6.81 (d, J= 6 
Hz, 2-H), 5.46 (s, 1H), 3.73 (t, J = 9Hz, 4-H), 3.05 (t, J = 9Hz, 4-H); 13C-NMR (75 MHz, 
CD3OD)  157.7, 152.4, 134.1, 131.4, 130.4, 129.0, 126.1, 125.9, 116.4, 67.2, 50.8, 49.3. 
MS (ESI) m/z 337 (M+H)
+
. C18H20N6O. 
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(3-methoxyphenyl)(1-(3,4,5-trimethoxyphenyl)-1H-tetrazol-5-yl)methanamine (60). 
Dark yellow oil (71 %). IR (KBr) 3376, 3289, 1601, 1463, 1125, 996, 774, 696 cm
-1
; 1H-
NMR (300 MHz, CD3OD)  7.21 (t, J= 15 Hz, 1-H), 6.86- 6.74 (m, 3-H), 6.55 (s, 2- H), 
5.64 (s, 1H), 3.77 (s, 3-H), 3.70 (s, 9-H); 13C-NMR (75 MHz, CD3OD)  160.8, 157.1, 
154.3, 140.2, 139.4, 130.8, 129.3, 120.3, 115.0, 114.2, 113.2, 104.4, 60.7, 56.4, 55.3, 51.4; 
MS (ESI) m/z 372 (M+H)
+
. C18H21N5O4. 
 
 
 
Biphenyl-4-yl(2-phenyl-2H-tetrazol-5-yl)methanamine (61). The reaction mixture was 
filtered through a Celite pad, evaporated under vacuum and purified by column 
chromatography, using petroleum ether/EtOAc 3:7 and then EtOAc as eluant to give a 
yellow amorphous solid (60 %). IR (KBr) 3410, 3300, 1617, 1116, 760, 692 cm
-1
; 1H-
NMR (300 MHz, CD3OD)  7.44-7.10 (m, 14-H), 5.36 (s, 1H); 13C-NMR (75 MHz, 
CD3OD)  158.9, 141.7, 140.8, 139.6, 134.2, 131.3, 130.4, 129.4, 128.1, 127.9, 127.7, 
127.4, 126.3, 51.2. MS (ESI) m/z 328 (M+H)
+
. C20H17N5.  
120 
 
 
 
 
(4-chlorophenyl)(2-(4-morpholinophenyl)-2H-tetrazol-5-yl)methanamine (62). Off-
white solid (92 %). IR (KBr) 3371, 3290, 2859, 2630, 1523, 1451, 1237, 1126, 926, 697 
cm
-1
; 1H-NMR (300 MHz, CD3OD)   7.42-7.34 (m, 2-H), 7.22 (d, J= 9 Hz, 2-H), 7.09-
7.01 (m, 5-H), 5.98 (s, 1-H), 3.84 (t, J = 9Hz, 4-H), 3.24 (t, J = 9Hz, 4-H); 13C-NMR (75 
MHz, CD3OD)   153.6, 152.4, 132.5, 131.3, 130.3, 129.3, 127.2, 125.6, 117.1, 66.9, 50.8, 
50.0; Mp= 231-234 °C. MS (ESI) m/z 371 (M+H)
+
. C18H19ClN6O. 
 
 
 
5-(5-(amino(3,4,5-trimethoxyphenyl)methyl)-2H-tetrazol-2-yl)-2-methoxyphenol (63). 
Colourless oil (66 %). IR (KBr) 3400, 3300, 2839, 1507, 1464, 1126, 1017, 904, 867 cm
-1
; 
1H-NMR (300 MHz, CD3OD)   7.00 (d, J= 9 Hz, 1-H), 6.70 (dd, Jo,m = 12Hz,6Hz, 1-H), 
6.60 (s, 1-H), 6.49 (s, 2-H), 5.89 (s, 1-H), 3.90 (s, 3-H), 3.72 (s, 9-H); 13C-NMR (75 MHz, 
CD3OD)   154.6, 153.9, 150.7, 148.1, 140.0, 128.1, 126.3, 117.9, 113.3, 112.3, 106.6, 
60.8, 56.3, 51.2; MS (ESI) m/z 386.1 (M-H)
-
; Mp= 138- 140°C. C18H21N5O5.  
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(1-(3-methoxyphenyl)-1H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl)methanamine (64). 
Brownish solid (92 %).IR (KBr) 3370, 3296, 2623, 1599, 1129, 1035, 988, 843 cm
-1
; 1H-
NMR (300 MHz, CD3OD)  7.43 (t, J= 18 Hz, 1-H), 7.12 (dd, Jo,m = 12Hz,6Hz, 1-H), 
6.91(d, J= 6 Hz, 1-H), 6.77 (s, 1-H), 6.54 (s, 2-H), 6.03 (s, 1-H), 3.75 (s, 3-H), 3.71 (s, 6-
H), 3.69 (s, 3-H); 13CNMR (75 MHz, CD3OD)  161.6, 154.8, 153.7, 140.2, 134.8, 131.6, 
127.9, 118.6, 117.8, 112.2, 106.9, 60.8, 56.5, 56.1, 51.1; Mp= 227-230 °C. MS (ESI) m/z 
372 (M+H)
+
; Mp= 138-140°C. C18H21N5O4. 
 
 
 
(1-(4-methoxyphenyl)-1H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl)methanone (22). The 
crude material was purified by column chromatography, using petroleum ether/EtOAc 7:3 
as eluant to give a yellowish solid (50 %). IR (KBr) 2945, 1655, 1472, 1339, 1133, 833, 
775 cm
-1
; 1H-NMR (300 MHz, CDCl3)  7.58 (s, 2-H), 7.40 (d, J = 9 Hz, 2-H), 7.01 (d, J 
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= 9 Hz, 2-H), 3.97 (s, 3-H), 3.90 (s, 6-H), 3.86 (s, 3-H); 13C-NMR (75 MHz, CDCl3)  
179.4, 160.7, 152.8, 149.6, 144.5, 129.1, 126.5, 126.0, 114.2, 108.0, 60.7, 55.9, 55.2; MS 
(ESI) m/z 371 (M+H)
+
; Mp=156-159°C. C18H18N4O5 (370,1): calcd. C 58.37, H 4.90, N 
15.13; found C 58.30, H 5.10, N 15.30. 
 
 
 
 
(1-(4-methoxyphenyl)-1H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl)methanone (65). The 
crude material was purified by column chromatography, using petroleum ether/EtOAc 7:3 
as eluant to give a yellowish solid (50 %). IR (KBr) 2930, 1600, 1512, 1280, 1173, 1026, 
926, 843 cm
-1
; 1H-NMR (300 MHz, CDCl3)  7.58 (s, 2-H), 7.40 (d, J = 9 Hz, 2-H), 7.01 
(d, J = 9 Hz, 2-H), 3.97 (s, 3-H), 3.90 (s, 6-H), 3.86 (s, 3-H); 13C-NMR (75 MHz, CDCl3) 
 179.7, 165.3, 153.2, 149.9, 139.2, 133.0, 129.1, 127.5, 114.1, 102.3, 60.6, 56.0, 55.4; MS 
(ESI) m/z 392 (M+Na)
+
; Mp=134-135 °C. C18H18N4O5 (370,1): calcd. C 58.37, H 4.90, N 
15.13; found C 58.60, H 5.15, N 15.00. 
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Biphenyl-4-yl(2-(4-phenoxyphenyl)-2H-tetrazol-5-yl)methanone (66). The crude 
material was purified by column chromatography, using petroleum ether/EtOAc 7:3 as 
eluant to give an amorphous orange solid (44 %). IR (KBr) 2860, 1630, 1452, 1121, 1049, 
734, 697 cm
-1
; 1H-NMR (300 MHz, CDCl3)   8.33 (d, J = 9 Hz, 2-H), 7.76 (d, J = 9 Hz, 
2-H), 7.65 (d, J = 6Hz, 2-H), 7.51-7.37 (m, 5-H), 7.19 (t, J = 15Hz, 1-H), 7.08 (d, J = 9 Hz, 
2-H); 13C-NMR (75 MHz, CDCl3)   181.0, 159.8, 155.7, 150.1, 148.3, 139.4, 133.6, 
131.7, 130.3, 129.2, 128.9, 128.6, 127.7, 127.5, 126.78, 124.8, 120.2, 118.5. MS (ESI) m/z 
419 (M+H)
+
; C26H18N4O2 (418,1): calcd. C 74.63, H 4.34, N 13.39; found C 74.80, H 4.50, 
N 13.40. 
 
 
 
(2-(benzo[d][1,3]dioxol-5-yl)-2H-tetrazol-5-yl)(3,4,5,-trimethoxyphenyl)methanone 
(67). The crude material was purified by column chromatography, using petroleum 
ether/EtOAc 7:3 as eluant to give a yellowish solid (63 %). IR (KBr) 2894, 1620, 1504, 
1474, 1336, 1124, 995, 860 cm
-1
; 1H-NMR (300 MHz, CDCl3)  7.55 (s, 2-H), 6.93-6.88 
(m, 3-H), 6.07 (s, 2-H), 3.95 (s, 3-H), 3.89 (s, 6-H); 13C-NMR (75 MHz, CDCl3)  179.8, 
153.3, 150.1, 149.6, 148.4, 145.0, 129.6, 127.8, 119.3, 108.5, 108.4, 106.4, 102.6, 61.2, 
56.4; MS (ESI) m/z 385 (M+H)
+
; Mp = 109- 112 °C. C18H16N4O6 (384,1): calcd. C 56.25, 
H 4.20, N 14.58; found C 55.90, H 4.00, N 14.70. 
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(2-(4-phenoxyphenyl)-2H-tetrazol-5-yl)(3,4,5,-trimethoxyphenyl)methanone (68). The 
crude material was purified by column chromatography, using petroleum ether/EtOAc 8:2 
as eluant to give a yellowish solid (50 %). IR (KBr) 2831, 1630, 1507, 1414, 1383, 1244, 
1127, 837 cm
-1
; 1H-NMR (300 MHz, CDCl3)  7.59 (s, 2-H), 7.44-7.39 (m, 4-H), 7.18 (t, J 
= 12Hz, 1-H), 7.10-7.05 (m, 4-H), 3.97 (s, 3-H), 3.90 (s, 6-H); 13CNMR (75 MHz, CDCl3) 
 18.00, 159.9, 155.7, 153.4, 150.2, 145.2, 130.4, 129.7, 128.7, 126.8, 124.9, 120.3, 118.5, 
108.7, 61.3, 56.6; MS (ESI) m/z 433.06 (M+H)
+
 ; Mp = 183-185°C. C23H20N4O5 (432,1): 
calcd. C 63.88, H 4.66, N 12.96; found C 64.05, H 4.80, N 12.90. 
 
 
 
(2-(benzo[d][1,3]dioxol-5-yl)-2H-tetrazol-5-yl)(3-hydroxy-4-methoxyphenyl) 
methanone (69) The crude material was purified by column chromatography, using 
EtOAc as eluant to give a light yellow solid (46 %). IR (KBr) 1645, 1505, 1282, 1126, 
1036, 778 cm
-1
; 1H-NMR (300 MHz, DMSO-d6)   7.68 (d, J= 9Hz, 1-H), 7.54 (s, 1-H), 
7.27 (s, 1-H), 7.12-7.06 (m, 3-H), 6.16 (s, 2-H), 3.88 (s, 3-H); 13C-NMR (75 MHz, 
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DMSO-d6)   180.5, 155.2, 150.9, 149.7, 148.5, 147.5, 128.3, 128.1, 126.1, 120.3, 116.4, 
112,3, 109.0, 107.4, 103.2, 56.7; MS (ESI) m/z 339.0 (M-H)
-
 ; Mp = 220- 223 °C. 
C16H12N4O5 (340,1): calcd. C 56.47, H 3.55, N 16.46; found C 56.60, H 3.70, N 16.70. 
 
 
 
(2-(benzo[d][1,3]dioxol-5-yl)-2H-tetrazol-5-yl)(4-chloro-3-methylphenyl)methanone 
(70). The crude material was purified by column chromatography, using petroleum 
ether/EtOAc 7:3 as eluant to give a yellow solid (40%). IR (KBr) 2920, 1635, 1471, 1383, 
1035, 922, 616 cm-1; 1H-NMR (300 MHz, CDCl3)  8.22 (m, 2-H), 7.71 (t, J= 18Hz, 1-H), 
7.58-7.52 (m, 2-H), 6.95-6.89 (m, 2-H), 6.09 (s, 2-H); 13C-NMR (75 MHz, CDCl3)  
181.7, 149.8, 148.6, 135.7, 135.0, 132.5, 131.1, 129.3, 127.3, 119.6, 108.6, 102.7; Mp = 
117-121 °C. MS (ESI) m/z 329 (M+H)
+
. C15H9ClN4O3 (328,0): calcd. C 54.81, H 2.76, N 
17.04; found C 55.00, H 2.90, N 16.90. 
 
 
 
(4-chlorophenyl)(2-phenyl-2H-tetrazol-5-yl)methanone (71). 2,2 eq of 4-formyl-1-
methylpyridinium benzenesulfonate were used. The crude material was purified by column 
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chromatography, using petroleum ether/EtOAc 9:1 as eluant to give a white solid (38 %). 
IR (KBr) 1675, 1503, 1303, 918, 767 cm
-1
; 1H-NMR (300 MHz, CDCl3)   8.25-8.22 (m, 
2-H), 7.70 (t, J= 15Hz, 1-H), 7.57- 7.46 (m, 6-H); 13C-NMR (75 MHz, CDCl3)  182.2, 
150.6, 136.2, 135.4, 134.8, 133.7, 133.0, 131.6, 131.4, 130.3, 130.1, 129.7, 125.8, 125.6; 
Mp = 85-87 °C. MS (ESI) m/z 285 (M+H)
+
. C14H9ClN4O (284,0): calcd. C 59.06, H 3.19, 
N 19.68; found C 59.30, H 3.40, N 19.30. 
 
 
 
(4-morpholinophenyl)(2-phenyl-2H-tetrazol-5-yl)methanone (72). The crude material 
was purified by column chromatography, using petroleum ether/EtOAc 7:3 as eluant to 
give a yellow solid (61%). IR (KBr) 1610, 1395, 1250, 1191, 929 cm
-1
; 1H-NMR (300 
MHz, CDCl3)  8.09 (d, J= 9Hz, 2-H), 7.51-7.46 (m, 5-H), 6.86 (d, J= 9Hz, 2-H), 3.82 (t, J 
= 9Hz, 4-H), 3.39 (t, J = 9 Hz, 4-H); 13C-NMR (75 MHz, CDCl3)  179.6, 156.3, 151.3, 
135.1, 134.2, 131.2, 130.3, 125.7, 125.5, 113.6, 67.2, 47.6; MS (ESI) m/z 336.2 (M+H)
+
 ; 
Mp = 164-167 °C. C18H17N5O2 (335,1): calcd. C 64.47, H 5.11, N 20.88; found C 64.45, H 
5.30, N 20.80. 
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3-methoxyphenyl)(2-(3,4,5-trimethoxyphenyl)-2H-tetrazol-5- yl)methanone (73). 2,2 
eq of 4-formyl-1-methylpyridinium benzenesulfonate were used. The crude material was 
purified by column chromatography, using petroleum ether/EtOAc 7:3 as eluant to give a 
yellow solid (41 %). IR (KBr) 1632, 1506, 1339, 1277, 1127, 942 cm
-1
; 1H-NMR (300 
MHz, CDCl3)  7.73-7.76 (m, 1-H), 7.66 (t, J = 6Hz, 1-H), 7.42 (t, J= 15Hz, 1-H), 7.25-
7.05 (m, 1-H), 6.71 (s, 2-H), 3.86 (s, 3-H), 3.84 (s, 3-H), 3.81 (s, 6-H); 13C-NMR (75 
MHz, CDCl3)  182.7, 161.1, 154.6, 151.1, 137.0, 131.2, 130.4, 125.0, 123.6, 123.5, 115.0, 
103.8, 62.0, 57.5, 56.6; MS (ESI) m/z 371 (M+H)
+
 ; Mp = 94-99 °C. C18H18N4O5 (370,1): 
calcd. C 58.37, H 4.90, N 15.13; found C 58.45, H 5.10, N 15.13. 
 
 
 
Biphenyl-4-yl(2-phenyl-2H-tetrazol-5-yl)methanone (74). The crude material was 
purified by column chromatography, using petroleum ether/EtOAc 9:1 as eluant to give a 
white solid (39 %). IR (KBr) 1668, 1600, 1481, 1306, 924 cm
-1
; 1H-NMR (300 MHz, 
CDCl3)  8.32 (d, J= 9Hz, 2-H), 8.76 (d, J= 9Hz, 2-H), 7.65 (d, J= 6Hz, 2-H), 7.56-7.43 
(m, 8-H); 13C-NMR (75 MHz, CDCl3)  181.7, 150.8, 148.9, 140.0, 134.2, 132.3, 131.7, 
131.5, 130.4, 129.9, 129.6, 128.4, 128.2, 125.7; MS (ESI) m/z 327 (M+H)
+
 ; Mp = 129-132 
°C. C20H14N4O (326,1): calcd. C 73.61, H 4.32, N 17.17; found C 73.80, H 4.56, N 17.43. 
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(4-chlorophenyl)(2-(4-morpholinophenyl)-2H-tetrazol-5-yl)methanone (75). The crude 
material was purified by column chromatography, using petroleum ether/EtOAc 6:4 as 
eluant to give a yellow solid (46 %). IR (KBr) 1640, 1520, 1447, 1303, 1113, 927, 819. 
cm
-1
; 1H-NMR (300 MHz, CDCl3)  8.21 (d, J= 6Hz, 2-H), 7.54 (d, J= 6Hz, 2-H), 7.35 (d, 
J= 9Hz, 2-H), 7.93 (d, J= 9Hz, 2-H), 3.84 (t, J = 9Hz, 4-H), 3.23 (t, J = 9 Hz, 4-H); 
13CNMR (75 MHz, CDCl3)  182.6, 153.3, 150.7, 136.2, 135.7, 131.7, 129.8, 126.89, 
126.8, 126.0 115.8, 67.5, 49.0; Mp = 124- 128 °C. MS (ESI) m/z 370 (M+H)
+
. 
C18H16ClN5O2 (369,1): calcd. C 58.46, H 4.36, N 18.94; found C 57.92, H 4.24, N 19.10. 
 
 
 
(2-(3-hydroxy-4-methoxyphenyl)-2H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl) 
methanone (76). The crude material was purified by column chromatography, using 
petroleum ether/EtOAc 7:3 as eluant to give a yellow solid (46 %). IR (KBr) 1643, 1514, 
1255, 1124, 1021, 865 cm
-1
; 1H-NMR (300 MHz, CDCl3)  7.55 (s, 2-H), 7.01 (d, J= 3Hz, 
1-H), 7.97 (d, J= 3Hz, 1-H), 6.94 (s, 1- H), 3.97 (s, 3-H), 3.94 (s, 3-H), 3.89 (s, 6-H); 13C-
NMR (75 MHz, CDCl3)  181.0, 154.2, 151.0, 149.4, 147.4, 145.9, 130.6, 128.3, 117.8, 
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112.7, 111.6, 109.4, 62.1, 57.4, 57.2; MS (ESI) m/z 385 (M-H)
-
 ; Mp = 166-169 °C. 
C18H18N4O6 (386,1): calcd. C 55.96, H 4.70, N 14.50; found C 56.22, H 4.83, N 14.30. 
 
 
 
(1-(3-methoxyphenyl)-1H-tetrazol-5-yl)(3,4,5-trimethoxyphenyl)methanone (77). 2,2 
eq of 4-formyl-1- methylpyridinium benzenesulfonate were used.he crude material was 
purified by column chromatography, using petroleum ether/EtOAc 6:4 as eluant to give a 
yellowish amorphous solid (38 %). IR (KBr) 1610, 1578, 1237, 1134, 842, 684 cm
-1
; 1H-
NMR (300 MHz, CDCl3)  7.55 (s, 2-H), 7.40 (t, J= 15Hz, 1-H), 7.08- 6.97 (m, 3-H), 3.97 
(s, 3-H), 3.89 (s, 3-H), 3.88 (s, 6-H); 13CNMR (75 MHz, CDCl3)  180.9, 161.3, 154.3, 
154.2, 151.1, 131.4, 130.5, 118.0, 117.9, 117.5, 109.4, 62.2, 57.5, 57.4, 56.7; MS (ESI) m/z 
371 (M+H)
+
; C18H18N4O5 (370,1): calcd. C 58.37, H 4.90, N 15.13; found C 58.62, H 4.95, 
N 15.30. 
 
 
 
130 
 
 
 
 
 
 
 
 
 
 
 
     EXPERIMENTAL SECTION 
PART II 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
131 
 
 
 
General informations. 
 
 
Melting points were recorded using Reichert melting point apparatus. Mass spectra were 
obtained either from an AEI MS-50 instrument using electron impact ionization (EI), from 
an AEI MS-9 using electron spray (ES), or from a MALDI-TOF type of instrument for the 
high resolution mass spectra (HRMS). Proton NMR (1H) spectra were recorded at 300 
MHz or at 500 MHz. Carbon NMR (13C) spectra were similarly recorded at 75 MHz on a 
Bruker AC-300 spectrometer, using a broadband decoupled mode with the multiplicities 
obtained using a JMOD or DEPT sequence. Chemical shifts (δ) are reported in parts per 
million (ppm) from tetramethylsilane. NMR experiments were carried out in 
deuterochloroform (CDCl3). The following abbreviations are used for the multiplicities: s: 
singlet, d: doublet, t: triplet, q: quartet, m: multiplet, brs: broad singlet for proton spectra. 
Coupling constants (J) are reported in Hertz (Hz). 
Infrared spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer. Flash 
chromatography was performed using Kieselgel Si 60, 40-63 μm particle sized silica gel 
(200-400 mesh). Visualization was achieved under a UVP mineralight UVGL-58 lamp, 
and by developing the plates with phosphomolybdic acid reagent or potassium 
permanganate (KMnO4). All reagents were obtained from commercial suppliers unless 
otherwise stated. Where necessary, organic solvents were routinely dried and/or distilled 
prior to use and stored over molecular sieves under nitrogen. Other solvents were dried by 
distillation from the following: tetrahydrofuran (sodium/benzophenone); dichloromethane 
(calcium hydride); toluene (CaH2). All reactions requiring anhydrous conditions were 
performed in flame-dried apparatus under a nitrogen atmosphere. Organic extracts were, in 
general, dried over anhydrous magnesium sulfate (MgSO4) or sodium sulfate (Na2SO4). 
 
 
1,1-bis(5-phenyl-1,3,4-oxadiazol-2-yl)ethanol (31). Procedure: A 50 mL round-bottom 
flask equipped with a magnetic stir bar and charged with 2-phenyl-1,3,4-oxadiazole (0.03 g, 
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0.2 mmol) and THF (0.5 mL) are allowed to cool to -78 °C for five min prior to addition of 
n-BuLi (1.6 M solution in hexanes, 0.13 mL, 0.21 mmol). The reaction mixture was 
allowed to stir at the same temperature for 1.5 h. The acid chloride (0.21 mmol) was added 
dropwise to the solution. The solution was stirred for additional 2 h. The reaction mixture 
was poured onto a mixture of AcOEt (5 mL) and saturated aqueous NaHCO3 (5 mL). The 
organic layer was washed with water (2 x 5 mL), dried, and concentrated in vacuo. The 
resulting residue was purified by silica gel flash column chromatography (2:1 n-heptane/ 
AcOEt) and the organics concentrated in vacuo to provide the title compounds. IR: 3211, 
2362, 1731, 1558, 1448, 1155 cm
-1
; 1H-NMR (300 MHz, CDCl3)  δ 7.93 (d, J= 9 Hz, 4-H), 
7.47-7.18 (m, 6-H), 2.23 (s, 2-H); 13C-NMR (75 MHz, CDCl3) δ 166.1, 132.6, 129.4, 
127.3, 123.6, 68.3, 25.6. C18H14N4O3 
 
 
 
N-(3-isopropylquinazolin-4(3H)-ylidene)propan-2-amine (45). Procedure: To a 
solution of 2-iodophenyl isocyanide  (336 mg, 1.47 mmol) in anhydrous tetrahydrofuran 
(15 mL), kept in an oven-dried 25 mL- flask under an atmosphere of dry argon, was added 
dropwise with stirring a 1.35 M solution of nBuLi in hexane (1.1 mL, 1.47 mmol) at –78 
°C over a period of 5 min. The mixture was stirred at –78 °C for an additional 10 min, then 
diisopropylcarbodiimide (1.47 mmol) in anhydrous THF (1.47 mL) was added dropwise. 
The mixture was stirred at –78 °C for 3 h, and the reaction was quenched with saturated 
NH4Cl solution (1.47 mL). The mixture was warmed to r.t., diluted with AcOEt (35 mL), 
the organic phase washed with water (2 × 10 mL), brine (20 mL) and dried over anhydrous 
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Na2SO4. The solvents were removed under reduced pressure to give a crude product, which 
was purified by flash chromatography on silica gel  (2:1 n-heptane/ AcOEt), ( 14 %). IR: 
2963, 2359, 1596, 1471, 1272, 1135 cm
-1
; 1H-NMR (300 MHz, CDCl3)  δ 7.85 (d, J= 8 Hz, 
1-H), 7.79 (s, 1-H), 7.27 (d, J= 6 Hz, 2-H), 7.26-7.22 (m, 2-H),  5.15 (m, 1-H), 4.39 (m, 1-
H), 1.31 (d, J= 7 Hz, 6-H), 1.21(d, J= 6 Hz, 6-H). C14H19N3 
 
 
 
 
N-(2-butyl-3-isopropylquinazolin-4(3H)-ylidene)propan-2-amine (46). The following 
product is the second spot isolated from the previous reaction. (7%). IR: 2963, 2359, 1635, 
1579, 1556, 1239 cm
-1
; 1H-NMR (300 MHz, CDCl3)  δ 7.67 (d, J= 8 Hz, 1-H), 7.43-7.38 
(m, 2-H), 7.17-7.11 (m, 1-H), 4.27-4.23 (m, 1-H), 4.16-4.12 (m, 1-H), 1.57-1.55 (m, 2-H), 
1.23-1.05 (m, 19-H); 13C-NMR (75 MHz, CDCl3) δ 146.09, 142.58, 131.19, 127.24, 
126.99, 124.51, 120.34, 53.92, 49.03, 24.98, 23.46. C18H27N3 
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tert-butyl(2-(N,N’-diisopropylcarbamimidoyl)phenyl)carbamate (55). Procedure: The 
reaction mixture was purified by flash chromatography (9:1 n-heptane/ AcOEt, Rf= 0.4) 
( 11 %). IR: 2960, 1631, 1594, 1474, 1241, 1136 cm
-1
; 1H-NMR (300 MHz, CDCl3)  δ 
7.38-7.37 (m, 2-H), 7.20-7.15 (m, 2-), 4.55-4.53 (m, NH), 4.04-3.97 (m, 1-H), 1.64 (s, 1-
NHBoc), 1.27-1.12 (m, 21-H).  C18H29N3O2 
 
 
 
N-(3-isopropyl-2-(trimethylsilyl)quinazolin-4(3H)-ylidene)propan-2-amine (61). 
Procedure: A 50 mL round-bottom flask equipped with a magnetic stir bar and charged 
with 45 (0.05 g, 0.2 mmol) and THF (0.5 mL) are allowed to cool to -78 °C for five min 
prior to addition of n-BuLi (1.35 M solution in hexanes, 0.15 mL, 0.24 mmol). The 
reaction mixture was allowed to stir at the same temperature for 0.5 h. Trimethylsylil-
chloride (0.24 mmol) was added dropwise to the solution. The solution was stirred for 
additional 0.5 h. The reaction mixture was poured onto a mixture of AcOEt (5 mL) and 
saturated aqueous NaHCO3 (5 mL). The organic layer was washed with water (2 x 5 mL), 
dried, and concentrated in vacuo. The crude 1H-NMR  spectrum is reported (98 % 
conversion) (300 MHz, CDCl3)  δ 7.91-7.88 (m,1-H), 7.54-7.52 (m,1-H), 7.43-7.40 (m,1-
H),  7.34-7.29 (m,1-H), 5.18-5.09 (m,1-H), 4.43-4.36 (m,1-H), 1.41 (d, J= 7 Hz, 6-H), 1.28 
(d, J= 6 Hz, 6-H) ; C17H27N3Si 
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ethyl 4-(benzylamino)but-2-ynoate (10). Procedure: to the N-Boc protected amine (0.2 
g, 0.63 mmol) TFA ( 1.26 mL) was added at 0°C, and the solution was stirred for 0.5h. The 
reaction mixture was then diluted with DCM (5 mL), and saturated aqueous NaHCO3 (5 
mL), and extracted DCM (x3). The organic phases were washed with brine (10 mL) and 
concentrated in vacuo. The reaction mixture was purified by flash chromatography (2:1 n-
heptane/ AcOEt, Rf= 0.4) (52 %). 1H-NMR (300 MHz, CDCl3)  δ 7.38-7.27 (m, 5-H), 4.27 
(q, J= 21.4 Hz, 2-H), 3.90 (s, 2-H), 3.58 (s, 2-H), 1.69 (bs, NH), 1.35 (t,  J= 14.2 Hz, 3-H). 
C18H23NO4. 
 
 
 
General procedure for the Multi-Component Ugi/Aza-Wittig Reaction (75-77):  to a 
1mL round-bottom flask the aldehyde (1 eq) was added to a solution of amine (1eq) in 
ortho-dichlorobenzene (o-DCB), followed by the carboxylic acid (1 eq), N-
isocyanoiminotriphenylphosphorane (0.05 g, 0.165 mmol) and ammonium chloride (1.5 
eq). After completion of the reaction, monitored by TLC,  the solvent was filtered over 
silica equilibrated with n-heptane; the crude was then eluted with AcOEt, dried in vacuo 
and purified by flash chromatography.  
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Ethyl 4-(benzyl(3-methyl-1(5-(p-tolyl)-1,3,4-oxadiazol-2-yl)butyl)amino)but-2-ynoate 
(75). The reaction mixture was purified by flash chromatography (9:1 n-heptane/ AcOEt, 
Rf=0.2) ( 27 %). Yellowish amorphous solid. IR: 2956, 1709, 1498, 1242, 1053 cm
-1
; 1H-
NMR (300 MHz, CDCl3)  δ 7.98 (d, J= 9 Hz, 2-H), 7.41-7.28 (m, 7-H), 4.33 (t, J= 14.9 Hz, 
1-H), 4.08 (d, J= 13 Hz, 1-H),  4.08 (q, J= 21.3 Hz, 2-H),  3.73 (d, J= 13 Hz, 1-H), 3.59 (s, 
2-H), 2.45 (s, 2-H), 2.07-2.02 (m, 1-H), 1.88-1.80 (m, 2-H), 1.13 (t, J= 14.4 Hz, 3-H), 0.99 
(d, J= 6.2 Hz, 3-H), 0.91(d, J= 6.2 Hz, 3-H) ; 13C-NMR (75 MHz, CDCl3) δ 165.27, 
164.97, 153.03, 142.15, 137.67, 131.35, 129.69, 129.05, 128.52, 127.58, 126.97, 121.35, 
83.37, 61.97, 54.67, 39.37, 39.11, 24.63, 22.81, 21.95, 21.65, 13.79; MS (ESI) m/z 446.2 
(M+H)
+
; HRMS: 468.2242 (calc: 468.2263). C27H31N3O3 
 
 
 
Ethyl 5-(benzyl(3-methyl-1(5-(p-tolyl)-1,3,4-oxadiazol-2-yl)butyl)amino)pent-2-ynoate 
(76). The reaction mixture was purified by flash chromatography (4:1 n-heptane/ AcOEt, 
Rf=0.3) ( 48 %). Yellow amorphous solid. IR: 2924, 1706, 1438, 1254, 1117 cm
-1
; 1H-
NMR (300 MHz, CDCl3)  δ 8.03-7.95 (m, 2-H), 7.44-7.27 (m, 7-H), 4.26-4.13 (m, 3-H), 
3.97 (d, J= 14Hz, 1-H), 3.55 (d, J= 14Hz, 1-H), 3.10-3.01 (m, 1-H), 2.74-2.65 (m, 1-H), 
2.52-2.44 (m, 2-H), 2.46 (s, 3-H), 2.00-1.75 (m, 3-H), 1.31 (t, J= 14Hz, 3-H), 0.93 (d, J= 
6Hz, 3-H), 0.79 (d, J= 6Hz, 3-H) ; 13C-NMR (75 MHz, CDCl3) δ 165.79, 164.96, 153.65, 
142.33, 138.64, 130.23, 129.81, 129.19, 128.99, 128.43, 127.39, 126.92, 121.12, 87.30, 
74.04, 61.80, 55.57, 53.90, 48.44, 39.61, 24.44, 22.94, 21.82, 21.67, 19.33; MS (ESI) m/z 
460.2 [M+H]
+
; HRMS: 483.2463 (calc: 483.2420). C28H33N3O3 
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3-methyl-1(5-(p-tolyl)-1,3,4-oxadiazol-2-yl)butan-1-ol (77). The reaction mixture was 
purified by flash chromatography (4:1 n-heptane/ AcOEt, Rf=0.4) ( 37%). Yellowish oil.  
IR: 2956, 1688, 1612, 1499, 1176, 1138 cm
-1
; 1H-NMR (300 MHz, CDCl3)  δ 8.04-7.95 
(m, 2-H), 7.34-7.27 (m, 2-H), 5.14-5.09 (m, 1-H), 2.45 (s, 3-H), 1.99-1.81 (m, 3-H), 1.11-
1.01 (m, 6-H); 13C-NMR (75 MHz, CDCl3) δ 170.74, 167.94, 144.30, 142.50, 130.22, 
129.77, 129.16, 126.97, 120.82, 64.42, 43.92, 24.37, 23.01, 21.85, 21.66; MS (ESI) m/z 
247.1 [M+H]
+
; HRMS: 247.1444 [M+H]
+
;  (calc: 247.1447). C14H18N2O2 
 
 
 
3-methyl-N-phenethyl-1-(5-(p-tolyl)-1,3,4-oxadiazol-2-yl)butan-1-amine (87). The 
reaction mixture was purified by flash chromatography (7:1 DCM/ AcOEt, Rf=0.3) ( 74 %). 
Yellowish oil. IR: 2955, 1610, 1499, 1451, 1259, 1079 cm
-1
; 1H-NMR (300 MHz, CDCl3)  
δ 7.82 (d, J= 9 Hz, 2-H), 7.23-7.06 (m, 7-H), 4.03 (t, J= 15Hz, 1-H), 2.81-2.66 (m, 4-H), 
2.35 (s, 3-H), 1.65 (t, J= 12 Hz, 1-H),  1.57-1.50 (m, 2-H), 0.86 (d, J= 6 Hz, 3-H), 0.80 (d, 
J= 6Hz, 3-H); 13C-NMR (75 MHz, CDCl3) δ 167.79, 164.96, 142.17, 139.42, 129.67, 
128.63, 128.47, 126.88, 126.24, 121.17, 52.98, 48.54, 43.16, 36.18, 24.90, 22.45, 22.43; 
MS (ESI) m/z 350.2 [M+H]
+
; HRMS: 350.2239 (calc: 350.2232). C22H27N3O 
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N-(3-methyl-1(5-(p-tolyl)-1,3,4-oxadiazol-2-yl)butyl)-N-phenethyl-3-
phenylpropiolamide (92). Procedure: TEA (1.5 eq) and 3-phenylpropioloyl chloride (1.3 
eq) were added at 0°C to a DCM solution (0.5 mL) of the starting MCR adduct 87 (0.05 
mmol). The reaction is stirred for two hours at 0°C. The reaction was then diluted with 
DCM (2 mL) washed with water (3 mLx2), brine and the organic phase was evaporated 
under vacuum. The resulting mixture was purified by flash chromatography (4:1 n-
heptane/ AcOEt, Rf=0.4) ( 63%). Off-white amorphous solid. IR: 2941, 2206, 1629, 1495, 
1405 cm
-1
; 1H-NMR (300 MHz, CDCl3) 1:1 mixture of rotamers. δ 7.88-7.80 (m, 2-H), 
7.55-7.47 (m, 2-H), 7.39-7.30 (m, 3-H), 7.23-7.02 (m, 7-H), [6.12 (t, J= 15Hz); 5.91 (t, J= 
15Hz) 1-H], 3.74-3.67 (m, 1-H), 3.47 (t, J= 16Hz, 1-H), 2.91-2.74 (m, 1-H), 2.56-2.47 (m, 
1-H), 2.34 (s, 3-H), 2.19-1.91 (m, 2-H), 1.75-1.55 (m, 1-H), 1.02-0.95 (m, 6-H); 13C-NMR 
(75 MHz, CDCl3) δ 165.57 and 165.54, 164.71 and 164.31, 155.23 and 154.83, 142.73 and 
142.59, 138.43 and 137.77, 132.56 and 132.49, 130.43, 129.80 and 129.76, 128.80, 128.66 
and 128.53, 127.06 and 127.03, 126.76 and 126.50, 120.69 and 120.58, 120.15 and 120.07, 
91.29 and 91.03, 81.75 and 81.24, 53.24, 47.38, 46.92, 44.74, 39.24, 38.79, 36.90, 34.17, 
24.76 and 24.47, 22.76 and 22.71, 22.27 and 22.24, 21.65; MS (ESI) m/z 478.3 [M+H]
+
; 
HRMS: 500.2301 [M+Na]
+
;  (calc: 500.2314). C31H31N3O2 
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6-isobutyl-5-phenethyl-3-phenyl-2-(p-tolyl)-5,6-dihydro-4H-furo[2,3-c]pyrrol-4-one 
(93). Procedure: the starting MCR adduct 92 is dissolved in o-DCB (0.1M) and the 
reaction is stirred at 180°C overnight. The reaction mixture was purified by flash 
chromatography (9:1 n-heptane/ AcOEt, Rf=0.3) ( 87%). Yellowish amorphous solid.  IR: 
2925, 1688, 1454, 1352, 1178 cm
-1
; 1H-NMR (300 MHz, CDCl3)  δ 7.64-7.60 (m, 2-H), 
7.37-7.33 (m, 2-H), 7.29-7.13 (m, 8-H), 7.09-7.05 (m, 2-H), 4.14-4.01 (m, 2-H), 3.26-3.18 
(m, 1-H), 2.90-2.84 (m, 2-H), 2.29 (s, 2-H), 1.90-1.82 (m, 1-H), 1.68-1.37 (m, 3-H), 0.89-
0.80 (m, 6-H); 13C-NMR (75 MHz, CDCl3) δ 169.62, 164.66, 154.32, 139.23, 138.54, 
130.98, 129.27, 129.21, 128.79, 128.65, 128.44, 128.11, 127.55, 127.27, 126.48, 118.55, 
55.56, 42.12, 39.43, 35.45, 24.45, 23.88, 21.84, 21.36; MS (ESI) m/z 450.3 [M+H]
+
; 
HRMS: 472.2230 [M+Na]
+
;  (calc: 472.2252). C31H31NO2 
 
 
 
Ethyl 6-benzyl-7-isobutyl-2-(p-tolyl)-4,5,6,7-tetrahydrofuro[2,3-c]pyridine-3-carboxy 
late (79). Procedure: the starting MCR adduct 76 is dissolved in o-DCB (0.1M) and the 
reaction is stirred at 210°C for 28h. The reaction mixture was purified by flash 
chromatography (4:1 n-heptane/ AcOEt, Rf=0.3) ( 16%). 1H-NMR (300 MHz, CDCl3)  δ 
7.78 (d, J= 8 Hz, 2-H), 7.41-7.22 (m, 7-H), 4.30 (q, J= 22 Hz, 2-H), 3.74 (s, 2-H), 3.63 (t, 
J= 13 Hz, 1-H), 3.15-3.05 (m, 2-H), 2.89-2.86 (m, 2-H), 2.63-2.56 (m, 2-H), 2.40 (s, 3-H), 
1.96-1.87 (m, 1-H), 1.68-1.53 (m, 2-H), 1.34 (t, J= 14 Hz, 3-H), 0.93 (d, J= 6 Hz, 3-H), 
0.76 (d, J= 6 Hz, 3-H). C28H33NO3 
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